10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2020

or

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _________ to _________

Commission file number: 000-55857

CONVERSION LABS, INC.

(Exact name of registrant as specified in its charter)

Delaware	76-0238453
(State or other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
800 Third Avenue, Suite 2800, New York, NY New York, NY	10022
(Address of Principal Executive Offices)	(Zip Code)

(855) 743-6478

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of exchange on which registered
None	None	None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [  ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” a “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[  ]	Accelerated filer	[  ]
Non-accelerated filer	[X]	Smaller reporting company	[X]
		Emerging growth company	[  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act: [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

As of August 14, 2020, there were 71,063,444 shares of the registrant’s common stock outstanding.

CONVERSION LABS, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION
ITEM 1.	Financial Statements (unaudited)	3
	Condensed Consolidated Balance Sheets	4
	Condensed Consolidated Statements of Operations	5
	Condensed Consolidated Statements of Stockholders’ Equity (Deficit)	6
	Condensed Consolidated Statements of Cash Flows	7
	Notes to Condensed Consolidated Financial Statements
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	32
ITEM 4.	Controls and Procedures	32
PART II. OTHER INFORMATION
ITEM 1.	Legal Proceedings	33
ITEM 1A.	Risk Factors	33
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	34
ITEM 3.	Defaults Upon Senior Securities	34
ITEM 4.	Mine Safety Disclosures	34
ITEM 5.	Other Information	34
ITEM 6.	Exhibits	34
SIGNATURES		35

2

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

CONVERSION LABS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2020			December 31, 2019
ASSETS
Current Assets
Cash	$	336,151		$	1,106,624
Accounts receivable, net		436,025			97,448
Product deposit		281,143			150,000
Inventory, net		808,846			950,059
Other current assets		328,922			442,971
Total Current Assets	$	2,191,087		$	2,747,102
Non-current assets
ROU Asset		19,990			23,625
Capitalized Software, net		305,576
Intangible assets, net		507,646			675,452
Total non-current assets		833,212			699,077
Total Assets	$	3,024,299		$	3,446,179
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued expenses	$	5,789,399		$	3,051,156
Notes payable, net		1,070,945			814,734
Contract liabilities		303,670			109,552
Total Current Liabilities		7,164,014			3,975,442
Long-term Liabilities
Lease Liability		28,917			29,978
Contingent consideration on purchase of LegalSimpli		100,000			500,000
Liability to issue common stock		540,972			-
Deferred tax liability		70,000			70,000
Total Liabilities		7,903,903			4,575,420
Stockholders’ Equity (Deficit)
Common stock, $0.01 par value; 100,000,000 shares authorized, 71,063,440 and 53,404,045 shares issued, 70,548,248 and 52,888,845 outstanding as of June 30, 2020 and December 31, 2019, respectively		710,631			534,037
Additional paid-in capital		18,747,862			15,236,396
Accumulated (deficit)		(23,705,170	)		(16,594,917	)
		(4,246,675	)		(824,484	)
Treasury stock, 515,200 and 515,200 shares, at cost		(163,701	)		(163,701	)
Total Conversion Labs, Inc. Stockholders’ (Deficit)		(4,410,376	)		(988,185	)
Non-controlling interest		(469,226	)		(141,056	)
Total Stockholders’ (Deficit)		(4,879,602	)		(1,129,241	)
Total Liabilities and Stockholders’ (Deficit)	$	3,024,299		$	3,446,179

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

CONVERSION LABS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended June 30						Six Months Ended June 30,
	2020			2019			2020			2019
Product revenues, net		7,869,813			2,307,909			10,825,614			4,729,435
Software revenues, net		1,219,970			390,498			2,568,981			667,962
Service revenues, net								-
Total revenues, net	$	9,089,783		$	2,698,407		$	13,394,595		$	5,397,397
Cost of product revenue		2,118,001			589,690			3,462,161			1,199,866
Cost of software revenue		72,207			65,521			487,686			133,318
Cost of revenues		2,190,208			655,211			3,949,847			1,333,184
Gross Profit		6,899,575			2,043,196			9,444,748			4,064,213
Expenses
Selling & marketing expenses		8,394,331			2,215,913			11,140,213			4,206,894
General and administrative expenses		1,338,549			372,853			2,507,527			707,859
Operating expenses		203,260			95,477			327,751			181,263
Customer service expenses		89,482			141,278			257,667			268,216
Development Costs		92,325			50,838			170,467			96,515
Total expenses		10,117,947			2,876,360			14,403,625			5,460,747
Operating Loss		(3,218,372	)		(833,164	)		(4,958,877	)		(1,396,534	)
Interest (expense), net		(228,875	)		(129,826	)		(1,021,914	)		(300,020	)
Loss from continuing operations before provision for income taxes		(3,447,247	)		(962,990	)		(5,980,791	)		(1,696,554	)
Income taxes (Benefit)		-			-			-			-
Net Income (Loss)		(3,447,247	)		(962,990	)		(5,980,791	)		(1,696,554	)
Net (loss) income attributable to noncontrolling interests		(68,131	)		(144,887	)		(206,947	)		(214,702	)
Net Income (loss) attributable to Conversion Labs, Inc.		(3,379,116	)		(818,103	)		(5,773,844	)		(1,481,852	)
Basic loss per share attributable to Conversion Labs, Inc. from continuing operation	$	(0.06	)	$	(0.02	)	$	(0.10	)	$	(0.04	)
Diluted loss per share attributable to Conversion Labs, Inc. from continuing operation		(0.06	)		(0.02	)		(0.10	)		(0.04	)
Weighted Average number of common shares outstanding
Basic		61,743,697			46,882,305			57,616,266			46,844,736
Diluted		61,743,697			46,882,305			57,616,266			46,844,736

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

CONVERSION LABS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

	Conversion Labs, Inc.
					Additional
	Common Stock				Paid-in			Accumulated			Treasury						Noncontrolling
	Shares		Amount		Capital			(Deficit)			Stock			Total			interest			Total
Balance at December 31, 2019		53,403,649	$	534,037	$	15,236,396		$	(16,594,919	)	$	(163,701	)	$	(988,187	)	$	(141,056	)	$	(1,129,243	)
Stock compensation						95,900									95,900						95,900
Cashless exercise of warrants		739,291		7,389		(7,389	)								-						-
Distribution to non-controlling interest															-			(36,000	)		(36,000	)
Deemed distribution from down-round provision in common stock shares yet to be issued									(106,519	)					(106,519	)					(106,519	)
Deemed distribution from warrant price adjustments						1,142,385			(1,142,385	)					-						-
Net (loss)									(2,394,728	)					(2,394,728	)		(138,816	)		(2,533,544	)
Balance at March 31, 2020		54,142,940		541,426		16,467,292			(20,238,551	)		(163,701	)		(3,393,534	)		(315,872	)		(3,709,406	)
Stock issued for services		250,000		2,500		32,700									35,200						35,200
Stock compensation						438,575									438,575						438,575
Cashless exercise of warrants		4,216,200		42,162		(42,162	)								-						-
Purchase of common stock		1,470,600		14,706		235,294									250,000						250,000
Shares issued for share liability		10,983,700		109,837		1,616,163									1,726,000						1,726,000
Distribution to non-controlling interest															-			(85,223	)		(85,223	)
Deemed distribution from down-round provision in common stock shares yet to be issued									(87,503	)					(87,503	)					(87,503	)
Net (loss)									(3,379,116	)					(3,379,116	)		(68,131	)		(3,447,247	)
Balance June 30, 2020		71,063,440		710,631		18,747,862			(23,705,170	)		(163,701	)		(4,410,378	)		(469,226	)		(4,879,604	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

	Conversion Labs, Inc.
					Additional
	Common Stock				Paid-in		Accumulated			Treasury						Noncontrolling
	Shares		Amount		Capital		(Deficit)			Stock			Total			interest			Total
Balance at December 31, 2018		45,782,305	$	457,822	$	12,744,249	$	(12,140,670	)	$	(163,701	)	$	897,700		$	(77,962	)	$	819,738
Stock issued for services		100,000		1,000		15,000								16,000						16,000
Stock compensation		1,000,000		10,000		144,600								154,600						154,600
Distributions to non-controlling interest																	(34,298	)		(34,298	)
Net (loss)								(663,747	)					(663,747	)		(69,816	)		(733,563	)
Balance at March 31, 2019		46,882,305	$	468,822	$	12,903,849	$	(12,804,418	)	$	(163,701	)	$	404,552		$	(182,075	)	$	222,477
Agreement to issue shares for non-controlling interest in Conversion Labs PR								(1,319,407	)					(1,319,407	)		412,377			(907,030	)
Stock compensation						218,460								218,460						218,460
Net (loss)								(818,104	)					(818,104	)		(144,886	)		(962,990	)
Balance June 30, 2019		46,882,305		468,822		13,122,309		(14,941,929	)		(163,701	)		(1,514,499	)		85,416		$	(1,429,083	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

CONVERSION LABS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	2020			2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss) income	$	(5,980,791	)	$	(1,696,554	)
Adjustments to reconcile net (loss) income to net
cash provided by (used) in operating activities
Amortization of debt discount		739,324			86,268
Amortization of capitalized software		11,585			-
Amortization of intangibles		167,806			167,807
Acceleration of debt discount		500,145
Operating Lease Payments		2,574			3,453
Liability to issue shares for services		32,500			242,969
Stock issued for services		35,200			16,000
Stock compensation expense		534,475			373,060
Changes in Assets and Liabilities
Accounts receivable		(338,577	)		(4,218	)
Product deposit		(131,143	)		(98,275	)
Inventory		141,213			319,330
Other current assets		114,047			144,241
Deferred revenue		194,118			(3,871	)
Deferred tax liability		-			(4,000	)
Accounts payable and accrued expenses		2,880,243			1,113,972
Net cash (used in) provided by operating activities		(1,097,281	)		640,182
CASH FLOWS FROM INVESTING ACTIVITIES
Payment to seller for contingent consideration		(277,161	)		(500,000	)
Contingent consideration on business combination paid		(400,000	)		-
Net cash used in investing activities		(677,161	)		(500,000	)
CASH FLOWS FROM FINANCING ACTIVITIES
Shares issued for cash		250,000			-
Cash receipts from investors for unissued shares		1,639,000			-
Debt issuance costs		(15,000	)		-
Distributions to non-controlling interest		(121,223	)		(34,298	)
Proceeds from notes payable		1,750,000			50,000
Repayment of notes payable		(2,498,808	)		(70,870	)
Net cash provided by (used in) financing activities	$	1,003,969		$	(55,168	)
Net increase in cash		-770,473			85,014
Cash at beginning of the period		1,106,624			180,093
Cash at end of the period	$	336,151		$	265,107
Supplemental Disclosure of Cash Flow Information
Cash paid during the period for interest	$	349,791		$	4,383
Agreement to issue shares for non-controlling interest in Conversion Labs PR	$	-		$	907,031
Cashless exercise of warrants	$	49,551		$	-
Deemed distribution from down-round provision	$	1,142,385		$	-
Stock yet to be issued for capitalized costs	$	40,000		$	-
Deemed distribution from down-round provision on unissued shares	$	194,022		$	-
Shares issued for share liability	$	(1,726,000	)	$	-
Debt issuance costs for liability to issue shares	$	219,450		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

CONVERSION LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – NATURE OF THE ORGANIZATION AND BUSINESS

Nature of Business

Conversion Labs, Inc., was formed in the State of Delaware on May 24, 1994, under our prior name, Immudyne, Inc. We changed our name to Conversion Labs, Inc. on June 22, 2018. Further, in connection with changing its name, the Company changed its trading symbol to CVLB. On April 1, 2016, our majority-owned subsidiary, Immudyne PR LLC (“Immudyne PR”), which was initially formed for the purpose of a joint venture with the original owners of one of our skincare products, amended and restated its operating agreement whereby we increased our ownership and voting interest in Immudyne PR to 78.2%. Concurrent with the name change of the parent company to Conversion Labs, Inc. completed in 2018, Immudyne PR was renamed to Conversion Labs PR LLC (now known as “Conversion Labs PR”). On April 25, 2019, the operating agreement of Conversion Labs PR was amended and restated in its entirety after acquiring the remaining minority interest in the Conversion Labs PR, which is now a wholly-owned subsidiary of the Company.

In June 2018, Conversion Labs closed the strategic acquisition of 51% of LegalSimpli Software, LLC, a software as a service (SaaS) application for converting, editing, signing and sharing PDF documents. In addition to LegalSimpli Software’s growth business model, this acquisition added deep search engine optimization and search engine marketing expertise to the Company.

In early 2019, the Company also launched a service-based business under the name Conversion Labs Media LLC, which was to be used to run e-commerce marketing campaigns for other online businesses. However, this business was discontinued in 2019 in order to focus on its core business as well the expansion of our telehealth opportunities.

In June 2019, a strategic joint venture with GoGoMeds.com (GoGoMeds) was formed in order to help facilitate the launch of our telemedicine business. GoGoMeds is a nationwide pharmacy licensed to dispense prescription medications directly to consumers in all 50 states and the District of Columbia.

The Company is a direct to consumer response healthcare company that provides a convenient, cost-effective and smarter way for consumers to access high quality Over The Counter (OTC) products and prescription medications. The U.S. healthcare system is undergoing a paradigm shift largely due to new technologies and the emergence of direct-to-consumer healthcare. We believe the traditional model of visiting a doctor’s office, receiving a physical prescription, visiting a neighborhood pharmacy, and returning to see a doctor for follow up care or prescription refills is inefficient, costly to patients, and discourages many patients from seeking much needed medical care. Direct-to-consumer telemedicine companies, like our Company, offer patients immediate and virtual treatment from licensed physicians, and the home delivery of prescription medications, devices and diagnostics bundled with over-the counter wellness products.

We have built a platform that allows us to efficiently launch telehealth and wellness product lines wherever we determine there is a market need. Our platform is supported by a driven team of digital marketing and branding experts, data analysts, designers, and engineers focused on building enduring brands.

Unless otherwise indicated, the “Company” refers Conversion Labs, Inc. (formerly known as Immudyne, Inc.), our wholly subsidiary Conversion Labs PR, LLC (formerly Immudyne PR LLC, now “Conversion Labs PR”), a Puerto Rico limited liability company (“Conversion Labs PR”) and our majority-owned subsidiary LegalSimpli Software, LLC, a Puerto Rico limited liability company (“LegalSimpli”). Unless otherwise specified, all dollar amounts are expressed in United States dollars.

7

Liquidity

The Company has funded operations in the past through the sales of its products, issuance of common stock and through loans and advances from officers and directors. The Company’s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors, obtaining funding from third-party sources or the issuance of additional shares of common stock.

The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2020, the Company has an accumulated deficit approximating $23.7 million and has experienced significant losses from continuing operations. Based on the Company’s cash balance as of June 30, 2020, and projected cash needs, management estimates that it will need an additional $4.0 million through the next 12 months, either from increasing sales revenue and/or raising additional capital via the sale of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company. Based on these circumstances, management has determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”).

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Conversion Labs PR and its majority owned subsidiary, LegalSimpli. The non-controlling interest in LegalSimpli represents the 49% equity interest held by other members of the subsidiary. All significant consolidated transactions and balances have been eliminated in consolidation.

Use of Estimates

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the determination of reserves (if necessary) for accounts receivable, returns and allowances, useful life of intangible and right of use assets, the valuation of inventory and inputs into the provision for lease liabilities and stockholders’ equity-based transactions. Actual results could differ from those estimates.

Reclassifications

Certain reclassifications have been made to conform the prior year’s data to the current presentation. These reclassifications have no effect on previously reported operations, stockholders’ equity (deficit) or cash flows. Given the increase in the Company’s software business and to conform the Company’s presentation of operating results to industry standards, the Company has changed their categories for reporting operations, as result the Company has made reclassifications to the prior year presentation in order to conform it to the current presentation.

Revenue Recognition

The Company records revenue under the adoption of ASC 606 by analyzing exchanges with its customers using a five-step analysis:

1.	Identify the contract
2.	Identify performance obligations
3.	Determine the transaction price
4.	Allocate the transaction price
5.	Recognize revenue

8

For the Company’s product-based contracts with customers, the Company has determined that there is one performance obligation and the delivery of this performance obligation is transferred at a point in time. The Company generally records sales of finished products once the customer places and pays for the order and the product is simultaneously shipped by a third-party fulfillment service provider, but in limited cases if title does not pass until the product reaches the customer’s delivery site, then recognition of revenue should be deferred until that time, however the Company does not have a process to properly record the recognition of revenue if orders are not immediately shipped. Delivery is considered to have occurred when title and risk of loss have transferred to the customer, which is usually upon shipment of the product. The Company does sell a subscription based service which is based on the recurring shipment of products and billed as if the Company were receiving recurring revenues and orders each month, therefore, the Company records these upon each shipment to the customer.

The Company records an estimate for provisions of discounts, returns, allowances, customer rebates and other adjustments for each shipment, and are netted with gross sales. The Company’s discounts and customer rebates are known at the time of sale and the Company appropriately debits net product revenues for these transactions based on the known discount and customer rebates. The Company estimates for customer returns and allowances based on estimates of historical transactions and accounts for such provisions during the same period in which the related revenues are earned. The Company has determined that the population of contracts with customers tends to be homogenous, so that review of the contracts and estimate of various revenue related adjustments can be applied to the entire portfolio population. Customer discounts, returns and rebates on product revenues during the three months ended June 30, 2020 and 2019 approximated $857,000 and $161,000, respectively. Customer discounts, returns and rebates on product revenues during the six months ended June 30, 2020 and 2019 approximated $1,334,000 and $713,000, respectively. 

The Company, through its majority-owned subsidiary LegalSimpli, offers a suite of software to customers as a monthly subscription based service. This suite of software allows the user or subscriber to convert almost any type of document to other editable document type formats for easy editing. For these subscription-based contracts with customers, the Company offers a 14-day trial period which is billed at $1.95 for an initial period, a monthly subscription, or a yearly subscription to the Company’s software. The Company has estimated that there is one product and performance obligation that is delivered over time, as the Company allows the subscriber to access the service for the time period purchased. The Company allows the customer to cancel at any point during the billing cycle, in which case the customers subscription will not be renewed for the following month or year depending on the original subscription. The Company records the sales over the customers subscription period for monthly and yearly subscribers or at the end of the initial 14 day service period for customers who purchased the initial subscription. The Company offers a discount for the purchase of the monthly and yearly subscriptions, which must be paid at the initiation of the contract term, so that the Contract price is fixed at the contract initiation. Yearly and monthly subscriptions for the subscription are recorded net of the Company’s known discount rates. As of June 30, 2020 and December 31, 2019, the Company has accrued contract liabilities of approximately $304,000 and $110,000, respectively, which represent obligations on in-process monthly or yearly contracts with customers and yet to be recognized initial 14-day trial periods.

9

For the six months ended June 30, 2020 and 2019, the Company had the following disaggregated revenue :

	Six Months Ended June 30,
	2020		%			2019		%
Product revenues by Brand for Conversion Labs PR:
Shapiro MD	$	8,156,378		61	%	$	4,413,157		82	%
Rex MD		2,515,560		19	%		-		-
iNR Wellness		119,254		1	%		233,594		4	%
Purpurex		30,317		0	%		10,232		0	%
Scarology		4,105		0	%		18,726		0	%
Innate		0		0	%		4,081		0	%
Total product revenue for Conversion Labs PR	$	10,825,614		81	%	$	4,679,790		86	%
Software revenue for LegalSimpli		2,568,981		19	%		717,607		14	%
Total net revenue	$	13,394,595		100	%	$	5,397,397		100	%

Accounts Receivable

Accounts receivable are carried at original sales amount less an estimate made for returns, chargebacks, and discounts. Accounts receivables mainly consist of receivables from third-party merchant processors which are settled with a couple of days. Management determines the need, if any, for an allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers’ accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. As of June 30, 2020 and 2019, the Company had determined that an allowance for doubtful accounts reserve was not necessary. As of June 30, 2020 and December 31, 2019, the reserve for sales returns and allowances was approximately $351,000 and $82,000, respectively.

Inventory

As of June 30, 2020 and December 31, 2019, inventory consisted primarily of finished cosmetic products. Inventory is maintained at the Company’s third-party warehouse location, which is owned by a related party, in Pennsylvania and at Amazon fulfillment centers.

Inventory is valued at the lower of cost or net realizable value with cost determined on a first-in, first-out (“FIFO”) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to net realizable, if lower. As of June 30, 2020 and December 31, 2019, the Company recorded an inventory reserve in the amount of $34,657 and $12,500, respectively. The increase in our inventory reserve mainly is attributable to the lack of marketability for our INR Wellness product line. As of June 30, 2020 and December 31, 2019, the Company’s inventory consisted of the following:

	June 30, 2020		December 31, 2019
Raw materials and packaging components	$	291,033	$	37,542
Finished products		517,813		912,517
Total net inventory	$	808,846	$	950,059

Product Deposit

Many of our vendors require deposits when a purchase order is placed for goods or fulfillment services. These deposits typically ranging from 10% to 33% of the total purchased amount. Our vendors issue a credit memo when sending their final invoice, reducing the amount the Company owes for the deposit amount previously paid to the vendors. The Company capitalizes these product deposits until the inventory is received at the Company’s fulfillment centers. As of June 30, 2020 and December 31, 2019, the Company has approximately $281,000 and $150,000, respectively, of product deposits with multiple vendors for the purchase of raw materials or finished for products we sell online. As of June 30, 2020 and December 31, 2019, the vast majority of these product deposits are with one vendor that manufacturers the Company’s finished goods inventory for its Shapiro hair care product line.

10

Capitalized Software Costs

The Company capitalizes certain payroll and third-party costs related to internally developed software and amortize these costs using the straight-line method over the estimated useful life of the software, generally two years. The Company does not sell internally developed software other than through the use of subscription service. Certain development costs not meeting the criteria for capitalization, in accordance with Accounting Standards Codification (“ASC”) ASC 350-40 Internal-Use Software, are expensed as incurred. As of June 30, 2020 and 2019, the Company capitalized $317,160 and $0 related to internally developed software costs which is included in development. As of June 30, 2020, these costs include $40,000 in capitalized stock based compensation that was given to a third-party service provider. During the three months ending June 30, 2020 and 2019, the Company amortized $11,585 and $0 of capitalized software costs, respectively.

Intangible Assets

Intangible assets are comprised of customer relationship asset and purchased licenses with estimated useful lives of three years and indefinite lived, respectively. Intangible assets are amortized over their estimated lives using the straight-line method. Costs incurred to renew or extend the term of recognized intangible assets are capitalized and amortized over the useful life of the asset.

Impairment of Long-Lived Assets

Long-lived assets are evaluated for impairment whenever events or changes in circumstances have indicated that an asset may not be recoverable and are grouped with other assets to the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities (asset group). If the sum of the projected undiscounted cash flows (excluding interest charges) of an asset group is less than its carrying value and the fair value of an asset group is also less than its carrying value, the assets will be written down by the amount by which the carrying value of the asset group exceeded its fair value. However, the carrying amount of a finite-lived intangible asset can never be written down below its fair value. Any loss would be recognized in income from continuing operations in the period in which the determination is made.

Liability to Issue Common Stock

Liability to issue common stock represents liabilities of the Company for failing to issue shares of common stock timely to various consultants and or third-party investors in conjunction with various consulting, service, warrant or stock purchase agreements. As of June 30, 2020, the Company has a liability to issue 2,627,635 shares of common stock for $541,972 in fair value. During the six months ended June 30, 3020, the Company received $1,639,000 in cash from investors which was recorded as a liability to issue shares until such time as the shares were issued. The yet to be issued shares of common stock are valued based on the fair market value of the common stock price on the date of agreement or the purchase price specified in the stock purchase agreement.

Income Taxes

The Company files corporate federal and state tax returns. Conversion Labs PR and LegalSimpli file tax returns in Puerto Rico, both are limited liability companies and file separate tax returns with any tax liabilities or benefits passing through to its members.

The Company records current and deferred taxes in accordance with Accounting Standards Codification (“ASC”) 740, “Accounting for Income Taxes.” This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company’s tax returns for all years since December 31, 2016, remain open to taxing authorities.

11

Stock-Based Compensation

The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting or service period. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company’s common stock shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.

Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

Earnings (Loss) Per Share

Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.

Common stock equivalents comprising shares underlying 17,498,953 options and warrants for the three and six months ended June 30, 2020 have not been included in the loss per share calculations as the effects are anti-dilutive.

Fair Value of Financial Instruments

The carrying value of the Company’s financial instruments, including cash, accounts receivable, accounts payable and accrued expenses and the face amount of notes payable approximate fair value for all periods.

Concentrations of Risk

The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.

The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.

We are dependent on certain third-party manufacturers, although we believe that other contract manufacturers could be quickly secured if any of our current manufacturers cease to perform adequately. As of June 30, 2020 and December 31, 2019, we utilized two (2) suppliers for fulfillment services, two (2) suppliers for manufacturing finished goods, one (1) supplier for packaging and bottles and one (1) supplier for labeling. For the three and six months ended June 30, 2020 and the year ended December 31, 2019, we purchased 100% of our finished goods from two (2) manufacturers.

Recently Adopted Accounting Pronouncements

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. We do not expect the implementation of this new pronouncement to have a material impact on our consolidated financial statements.

12

In July 2017, the FASB issued ASU No. 2017-11, “Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features” (“ASU 2017-11”). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share (“EPS”) reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard was adopted on January 1, 2020 and did not have a material impact on the Company’s financial position, results of operations or cash flows.

Recent Accounting Pronouncements

All other accounting standards updates that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

NOTE 3 – INTANGIBLE ASSETS

As of June 30, 2020, the Company has the following amounts related to intangible assets:

	Gross Carrying Amount		Accumulated Amortization
Amortizable intangible assets
Customer relationship asset	$	1,006,840	$	(699,194	)
Indefinite lived intangible assets
Purchased licenses		200,000		-
	$	1,206,840	$	(699,194	)

As of December 31, 2019 the Company has the following amounts related to intangible assets:

	Gross Carrying Amount		Accumulated Amortization
Amortizable intangible assets:
Customer relationship asset	$	1,006,840	$	(531,388	)
Indefinite lived intangible assets:
Purchased licenses		200,000		-
	$	1,206,840	$	(531,388	)

The aggregate amortization expense of the Company’s intangible assets for the three months ended June 30, 2020 and 2019 was approximately $83,903 and $83,903, respectively. The aggregate amortization expense of the Company’s intangible assets for the six months ended June 30, 2020 and 2019 was approximately $167,806 and $167,806, respectively. Estimated amortization expense for 2020 and 2021 is approximately $336,000 and $140,000, respectively.

13

NOTE 4 – NOTES PAYABLE

On May 29, 2018, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Alpha Capital Anstalt (“Alpha”) and Brio Capital Master Fund Ltd. (“Brio”). Pursuant to the terms of the Purchase Agreement, the Company issued and sold to them senior secured convertible notes in the aggregate original principal amount of $550,000 (collectively, the “Alpha and Brio Notes”), and warrants to purchase up to 2,391,305 shares of the Company’s common stock (collectively the “Alpha and Brio Warrants”). The Alpha and Brio Notes matured on May 2019. Interest on the outstanding principal amount of the Alpha and Brio Notes compounded annually at the annual rate of twelve percent (12%), subject to adjustments. The Alpha and Brio Notes are convertible into the Company’s common stock, at the option of the holder, at any time following issuance, unless the conversion or share issuance under the conversion would cause the holder to beneficially own in excess of 4.99% of the Company’s common stock. The conversion price for the principal and interest, if any, in connection with voluntary conversion by the Holder shall be $0.23 per share of Common Stock, subject to adjustment as defined in the Alpha and Brio Notes. Alpha and Brio have converted $344,642 of these notes including $9,922 of interest as of December 31, 2019 and 2018. As of June 30, 2020, these notes have been paid off.

On August 15, 2019, the Company entered into securities purchase agreements (the “August Purchase Agreements”) with three accredited investors, including Alpha and Brio. Pursuant to the terms of the August Purchase Agreements, the Company issued and sold to the investors convertible promissory notes for the aggregate original principal amount of $1,291,500 (collectively the “August 2019 Notes”), and warrants to purchase up to 4,679,348   shares of the Company’s common stock (the “August 2019 Warrants”). The August 2019 Notes mature on August 15, 2020 and accrue interest at a rate of twelve percent (12%) per annum, subject to adjustments as defined therein. The August 2019 Notes may be converted into shares of the Company’s common stock, at the discretion of the holder, at any time following issuance, unless the conversion or share issuance under the conversion would cause the holder to beneficially own shares in excess of 4.99% of the Company’s common stock. The conversion price for the principal and interest, if any, in connection with voluntary conversion by the investors shall be $0.23 per share of common stock, subject to adjustment as defined therein. In conjunction with the August 2019 Notes, the Company issued the August 2019 Warrants with an exercise price of $0.28 per share. The fair value of August 2019 Warrants was determined to be $569,147 based on using the Black-Scholes pricing model. The August 2019 Warrants were evaluated by management and deemed to be equity-linked awards subject to ASC 810, Derivatives and Hedging. The August 2019 Notes contained an original issue discount of 20% or $215,250 which is the difference between the note face amount of $1,291,500 and the cash proceeds received from the investors. As part of this financing, the Company paid debt issuance costs $284,070 which are placed as a contra-debt account and amortized over the life of the loan.

On February 25, 2020, the Company entered into a Note Repayment and Warrant Amendment Agreement with Alpha and Brio, whereby the Company agreed to repay the outstanding balance of Alpha and Brio’s August 2019 Notes in the amount of $1,291,000, including principal and interest. As a result of this transaction, the Company accelerated debt discounts for warrants, issuance costs and original issue discount of $500,145, which was recognized through interest expense on the accompanying consolidated statement of operations. As of June 30, 2020 and December 31, 2019, the gross balance payable for these notes was $0 and $1,291,000, respectively. As of June 30, 2020 and December 31, 2019, the Company has cumulatively amortized $568,322 and $404,393 of the debt discounts costs including debt issuance costs, original issue discount, and discount for warrants issued in connection with the debt transaction, all of which is included in interest expense on the accompanying consolidated statement of operations. As of June 30, 2020 and December 31, 2019, the net balance payable for these notes was $0 and $627,426, respectively.  

On February 18, 2020, the Company entered into two purchase agreements (the “C6 Purchase Agreements”) for the purchase and sale of future revenue with C6 Capital, LLC (“C6”). Pursuant to the terms of the C6 Purchase Agreements, the Company issued and sold to C6 two loan agreements   in the aggregate original principal amount of $1,020,000. These loans contain an original purchase discount of 18%, or $270,000, in total, or $135,000 per agreement. C6 paid $375,000 per loan agreement for a total of $750,000. The Company paid debt issuance costs to C6 of $7,500 per agreement, or $15,000 in total, which was placed as a contra-debt account and will be amortized over the life of the loan. The loan agreements require the Company to pay all future receipts of the Company without recourse until such time as the purchased amount has been repaid. The loan agreements require the Company to make a daily average payment of $8,094 during the term of such agreements. As of June 30, 2020, the Company has made $161,904 in principal payments under these loan agreements. As of June 30, 2020, the gross balance payable for these loan agreements was $858,000, and the balance of the loan net of discounts was $600,424. For the three months ended March 31, 2020, the Company has amortized $27,329 of debt discount through interest expense on the accompanying statement of operations.

14

Beginning May 21, 2020 through May 27, 2020 the Company, issued convertible promissory notes (the “May 2020 Notes”) to six (6) accredited investors (each a “May 2020 Investor”, and collectively, the “May 2020 Investors”). The aggregate principal amount of the May 2020 Notes is $1,000,000 for which the Company received gross proceeds of $1,000,000. The May 2020 Notes are due and payable six months from the date of issuance. The May 2020 Notes entitle each holder to 12% interest upon Maturity. The May 2020 Notes may be converted into shares of the Company’s common stock at any time following the date of issuance at a conversion price of $0.50 per share, subject to adjustment.

As an inducement to enter into the transaction, the Company issued an aggregate of 665,000 shares of the Company’s restricted common stock to the May 2020 Investors. In the event of a default the outstanding balance of the May 2020 Notes shall increase to 130% and shall become immediately due and payable upon notice to the Company.

Total interest expense on notes payable, inclusive of amortization of debt discounts, amounted to $1,021,914 and $300,000 for the six months ended June 30, 2020 and 2019, respectively. Total interest expense on notes payable, inclusive of amortization of debt discounts, amounted to $228,875 and $129,826 for the three months ended June 30, 2020 and 2019, respectively.

In June 2020, the Company and its subsidiaries received loans in the aggregate amount of approximately $242,000 (the “PPP Loan”) under the new Paycheck Protection Program legislation administered by the U.S. Small Business Administration. These loans bear interest at one percent per annum (1.0%) and mature five years from the date of the first disbursement. The proceeds of the PPP Loan must be used for payroll costs, lease payments on agreements before February 15, 2020 and utility payments under agreements before February 1, 2020. At least 60% of the proceeds must be used for payroll costs and certain other expenses and no more than 40% may be used on non-payroll expenses. Proceeds from the PPP Loan used by the Company for the approved expense categories may be fully forgiven by the Small Business Administration if the Company satisfies applicable employee headcount and compensation requirements. The Company currently believes that a majority of the PPP Loan proceeds will qualify for debt forgiveness; however, there can be no assurance that the Company will qualify for forgiveness from the Small Business Administration until it occurs. 

NOTE 5 – STOCKHOLDERS’ EQUITY

Common Stock

During the month of February 2020, the Company entered into a stock purchase agreement with a third-party investor for the purchase of 4,000,000 shares of common stock at $0.16 per share for $640,000 in cash consideration.

During the month of March 2020, the entered into a stock purchase agreement with a third-party investor for the purchase of 1,250,000 shares of common stock at $0.16 per share for $200,000 in cash consideration.

During the month of March 2020, Alpha and Brio exercised their warrants in a cashless exercise for an aggregate of 1,836,155 common stock warrants to obtain 739,291 shares of common stock.

As of June 30, 2020, the Company received $540,972 in cash from investors which is recorded as a liability to issue shares until such time as the shares are issued.

Noncontrolling Interest

For the three months ended June 30, 2020 and 2019, the net loss attributed to the non-controlling interest amounted to $68,131 and $144,887, respectively. During the three months ended June 30, 2020 and 2019, the Company paid distributions to non-controlling shareholders of $85,223 and $0, respectively. For the six months ended June 30, 2020 and 2019, the net loss attributed to the non-controlling interest amounted to $246,947 and $214,742, respectively. During the six months ended June 30, 2020 and 2019, the Company paid distributions to non-controlling shareholders of $121,223 and $34,298, respectively.

On April 25, 2019, the Company entered into an membership purchase agreement with entities owned by the Company’s Chief Executive officer and Chief Technology Officer, Conversion Labs PR, and purchased the remaining 21.8% interest of Conversion Labs PR from the Company’s Chief Executive officer and Chief Technology Officer. As such, the Company now wholly-owns 100% of Conversion labs PR. In order to consummate this transaction, the Company agreed to issue 5 million shares of common stock based on the issuance price of $0.18 per share, equal to $900,000 to the Company’s Chief Executive Officer and Chief Technology Officer. The shares were not issued until August 6, 2019, and, as such, the Company has recorded a liability on the Company’s balance sheet as of June 30, 2019. The difference between the value of the stock issued and net book value of the transfer to accumulated deficit was recognized in non-controlling interest for a charge of $412,377.

Service-Based Stock Options

On January 20, 2020, the Company approved the transition of Mr. Sean Fitzpatrick from the role of the Company’s Chief Acquisition Officer, to the role of President of LegalSimpli. In connection with Mr. Fitzpatrick’s transition, the Company agreed to amend that certain services agreement entered into on July 23, 2018, by and between the Company and Mr. Fitzpatrick, to (i) decrease the number of options to purchase the Company’s common stock previously granted to Mr. Fitzpatrick from 5,000,000 options to 2,500,000 options, 650,000 of which are fully vested as of the effective date and (ii) amend the vesting schedule for the remaining 1,850,000 performance options to include four performance metrics that, if met, each trigger the vesting of 462,500 options. As a result of amendment, the Company cancelled 1,850,000 service based options with an exercise price of $0.30.

15

During the six months ended June 30, 2020 the Company issued 2.4 million stock options to three employees, two advisory board members, and one vendor of the Company. These stock options have a contractual term of 10 years and vest in 1/3 increments over a two to three year period.

The following is a summary of outstanding service-based options activity for the three months ended June 30, 2020:

	Options Outstanding Number of Shares			Exercise Price per Share		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price per Share
Balance at December 31 2019		15,045,000		$	0.20 - 0.40		4.78 years	$	0.30
Granted		2,400,000			0.23-1.50		7.29 years		0.57
Cancelled		(1,875,000	)	$	0.30		7.50 years		0.30
Expired		–			–		–		–
Balance at June 30, 2020		16,070,000		$	0.16 - 1.50		4.56 years	$	0.34
Exercisable December 31, 2019		11,805,416		$	0.20 - 0.40		3.76 years	$	0.25
Exercisable at June 30, 2020		14,430,416		$	0.20 - 0.40		4.38 years	$	0.26

Performance-Based Stock Options

On January 20, 2020, the Company approved the transition of Mr. Sean Fitzpatrick from the role of the Company’s Chief Acquisition Officer, to the role of President of LegalSimpli. In connection with Mr. Fitzpatrick’s transition, the Company agreed to amend that certain services agreement entered into on July 23, 2018, by and between the Company and Mr. Fitzpatrick, to (i) decrease the number of options to purchase the Company’s common stock previously granted to Mr. Fitzpatrick from 5,000,000 options to 2,500,000 options, 650,000 of which are fully vested as of the effective date and (ii) amend the vesting schedule for the remaining 1,850,000 performance options to include four performance metrics that, if met, each trigger the vesting of 462,500 options. As a result of amendment, the Company cancelled 1,850,000 service based options with an exercise price of $0.30.

The following is a summary of outstanding performance-based options activity for the three months ended June 30, 2020:

	Options Outstanding Number of Shares			Exercise Price per Share		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price per Share
Balance at December 31, 2019		6,825,000		$	0.25 - 0.40		5.59 years	$	0.34
Granted		100,000			1.50		9.25		1.50
Cancelled		(650,000	)		0.30- 0.30		8.06 years		0.30
Expired		–			–		–		–
Balance at June 30, 2020		6,275,000		$	0.25 – 1.50		5.39 years	$	0.36
Exercisable December 31, 2019		3,175,000		$	0.25 - 0.40		2.63 years	$	0.40
Exercisable at June 30, 2020		3,175,000		$	0.25 - 0.40		2.63 years	$	0.40

16

Warrants

The following is a summary of outstanding and exercisable warrants activity during the three months ended June 30, 2020:

	Warrants Outstanding Number of Shares			Exercise Price per Share		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price per Share
Balance at December 31, 2019		11,326,621		$	0.20 - 0.50		6.02 years	$	0.25
Warrants Granted		5,642,715			0.13 - 0.14		5.49 years		0.12
Warrants Exercised		(9,930,759	)		0.13 - 0.14		1.45 years		0.14
Warrants Expired		-			-		-		-
Balance at June 30, 2020		7,038,181		$	0.13 - 0.50		5.59 years	$	0.31
Exercisable December 31, 2019		10,330,244		$	0.20 - 0.50		6.24 years	$	0.31
Exercisable June 30, 2020		5,745,608		$	0.13 - 0.50		5.62	$	0.34

Alpha Capital Anstalt (“Alpha”) Warrants

On February 25, 2020, the Company and Alpha entered into a Note Repayment and Warrant Amendment Agreement (the “2018 Alpha Amendment”) whereby the Company agreed to (i) repay the outstanding balance of the convertible promissory note issued in favor of Alpha on May 29, 2018 in the amount of $224,145, including principal and interest (the “2018 Alpha Note”) and (ii) amend the exercise price of the warrant (the “2018 Alpha Warrant”) issued to Alpha in connection with the 2018 Alpha Note on May 29, 2018. The 2018 Alpha Warrant originally provided for the purchase of up to 1,956,522 shares of the Company’s common stock at an exercise price of $0.28 per share, none of which have been issued as of the date of the 2018 Alpha Amendment. Pursuant to the terms of the 2018 Alpha Warrant and in connection with the 2018 Alpha Amendment, the Company revised the exercise price of the Alpha 2018 Warrant from $0.28 per share to $0.135 per share and increased the number of shares issuable under the Alpha 2018 Warrant from 1,956,522 to 4,057,972 shares.

On February 25, 2020, the Company and Alpha entered into a Note Repayment and Warrant Amendment Agreement (the “2019 Alpha Amendment”) whereby the Company agreed to (i) repay the outstanding balance of the convertible promissory note issued in favor of Alpha on August 15, 2019 in the amount of $520,000, including principal and interest (the “August 2019 Alpha Note”) and (ii) amend the exercise price of the August 2019 Warrant issued to Alpha in connection with the 2019 Alpha Note on August 15, 2019. The August 2019 Warrant issued to Alpha originally provided for the purchase of up to 1,826,087 shares of the Company’s common stock at an exercise price of $0.28 per share, none of which have been issued as of the date of the 2019 Alpha Amendment. Pursuant to the 2019 Alpha Amendment, Alpha has agreed to the reduction of the exercise price of $0.28 to $0.23. Therefore, effective upon the date of the 2019 Alpha Amendment, the exercise price of the 2019 Alpha Warrant was reduced to $0.23, subject to further adjustment. However, for purposes of calculating additional shares to be issued to Alpha pursuant to the terms of the 2019 Alpha Warrant, the deemed exercise price will be $0.135, as if the exercise price were actually reduced to $0.135 and thereafter increased to $0.23. As a result of the above described reduction of the exercise price and the application of certain provisions of the 2019 Alpha Warrant, the amount of shares that may be purchased upon exercise of the 2019 Alpha Warrant after giving effect to the foregoing is increased to 3,787,439 shares of the Company’s common stock.

17

As a result of the above transactions, the Company has recorded a deemed distribution to Alpha for the price adjustments of the August 2019 Warrant issued to Alpha of $915,479 which is recorded in the statement of changes in stockholder’s equity as an increase in additional paid in capital and a reduction of accumulated deficit. During the month of March 2020, Alpha exercised a portion of their warrants in a cashless exercise, whereby Alpha exercised 1,336,155 common stock warrants to obtain 451,159 share of common stock.

On May 7, 2020, the Company agreed to further amend August 2019 Warrant issued to Alpha on August 15, 2019, as amended on February 25, 2020 (the “Second Alpha Warrant Amendment”). Specifically, pursuant to anti-dilution provisions contained therein, the Company agreed to amend the August 2019 Warrant issued to Alpha in order to increase the amount of shares able to be purchased thereunder by an additional 1,657,005 shares of the Company’s common stock or an aggregate of up to 5,444,444 shares (the “Alpha Warrant Shares”). On the same day, Alpha exercised, on a cashless basis, all of the August 2019 Warrants issued to Alpha, as amended, resulting in the issuance of 1,957,331 shares of the Company’s common stock to Alpha. Upon Alpha’s cashless exercise, the August 2019 Warrants issued to Alpha are no longer in force or effect and no additional issuances will be due or owing.

Brio Master Fund (“Brio”) Warrants

On February 25, 2020, the Company, and Brio entered into a Warrant Amendment Agreement to amend the exercise price of the warrant issued to Brio on May 29, 2018. The Brio 2018 Warrant originally provided for the purchase of up to 434,783 shares of the Company’s common stock at an exercise price of $0.28 per share, none of which have been issued as of the date of the 2018 Brio Warrant Amendment. Pursuant to the 2018 Brio Warrant Amendment, the Company agreed to revise the exercise price of the 2018 Brio Warrant from $0.28 per share to $0.135 per share and increased the number of shares issuable under the 2018 Brio Warrant from 434,783 to 466,989 shares.

On February 25, 2020, the Company, and Brio entered into a Note Repayment and Warrant Amendment Agreement whereby the Company agreed to (i) repay the outstanding balance of the Convertible Promissory Note issued in favor of Brio on August 15 , 2019 in the amount of $162,500, including principal and interest and (ii) amend the exercise price of the warrant issued to Brio in connection with the 2019 Brio Note on August 15, 2019. The Brio 2019 Warrant originally provide for the purchase of up to 570,652 shares of the Company’s common stock at an exercise price of $0.28 per share, none of which have been issued as of the date of the 2019 Brio Amendment. Pursuant to the 2019 Brio Amendment, Brio has agreed to the reduction of the exercise price of $0.28 to $0.23. Therefore, effective upon the date of the 2019 Brio Amendment, the exercise price of the 2019 Brio Warrant is reduced to $0.23, subject to further adjustment. However, for purposes of calculating additional shares to be issued to Brio pursuant to the terms of the 2019 Brio Warrant, the deemed exercise price will be $0.135, as if the exercise price were actually reduced to $0.135 and thereafter increased to $0.23. As a result of the above described reduction of the exercise price and the application of certain provisions of the 2019 Brio Warrant, the amount of shares that may be purchased upon exercise of the 2019 Brio Warrant after giving effect to the foregoing is increased to 1,183,575 shares of the Company’s common stock.

As a result of the above transactions, the Company has recorded a deemed distribution to Alpha for the price adjustments of the Alpha warrants of $226,906 which is recorded in the statement of changes in stockholder’s equity as an increase in additional paid in capital and a reduction of accumulated deficit. During the month of March 2020, Brio exercised a portion of their warrants in a cashless exercise, whereby Alpha exercised 500,000 common stock warrants to obtain 287,736 shares of common stock.

On May 7, 2020, the Company agreed to further amend those certain warrants issued to Brio on August 15, 2019, as amended on February 25, 2020. Specifically, pursuant to anti-dilution provisions therein, the Company agreed to amend the 2019 Brio Warrant in order to increase the amount of shares able to be purchased thereunder by an additional 517,814 shares of the Company’s common stock or an aggregate of up to 1,701,389. On the same day, Brio exercised on a cashless basis the Brio Warrants in full resulting in the issuance of 611,666 shares of the Company’s common stock to Brio. Upon Brio’s cashless exercise, the 2019 Brio Warrants are no longer in force or effect and no additional issuances will be due or owing.

18

Stock-based Compensation

The total stock-based compensation expense related to Service-Based Stock Options, Performance-Based Stock Options and Warrants issued for service amounted to approximately $439,000 and $191,000 for the three months ended June 30, 2020 and 2019, respectively. The total stock-based compensation expense related to Service-Based Stock Options, Performance-Based Stock Options and Warrants issued for service amounted to $535,000 and $373,000 for the six months ended June 30, 2020 and 2019, respectively. Such amounts are included in general and administrative expenses in the consolidated statement of operations.

NOTE 6– LEASES

The Company primarily leases office space and other equipment using month to month terms. Conversion Labs PR utilizes office space in Puerto Rico which is subleased from Mr. Schreiber (the Company’s President and CEO) on a month to month basis and incurs expense of approximately $4,000 a month for this office space.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes all existing guidance on accounting for leases in ASC Topic 840. ASU 2016-02 is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. ASU 2016-02 will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We have reviewed ASC 842 and have determined the following impact on our financial statements:

	2020
Right of Use Asset		19,990
Lease liability		28,917

In February 2018, the Company entered into a 3-year agreement to lease office space in Huntington Beach, California beginning on March 2, 2018. The rent is payable on a monthly basis in the amount of $2,106 for the first twelve months, $2,149 for the second twelve months and $2,235 for the third twelve months. A security deposit of $2,235 was paid for this lease. The Company has classified this as an operating lease and have recorded the straight-line lease expense in the accompanying statement of operations.

NOTE 7 - COMMITMENTS AND CONTINGENCIES

Royalty Agreements

During 2016, Conversion Labs PR entered into a sole and exclusive license, royalty and advisory agreement with Pilaris Laboratories, LLC (“Pilaris”) relating to Pilaris’ PilarisMax shampoo formulation and conditioner. The term of the agreement will be the life of the US Patent held by Pilaris. As consideration for granting Conversion Labs PR this license, Pilaris will receive on quarterly basis, 10% of the net income collected by the licensed products based on the following formula: Net Income = total income – cost of goods sold – advertising and operating expenses directly related to the marketing of the licensed products. In addition, Conversion Labs PR shall pay Pilaris a performance fee of $50,000 on the 180-day anniversary of the agreement and an additional $50,000 performance fee on the 365-day anniversary of the agreement. For the year ended December 31, 2018, the Company capitalized the license fee in the amount of $100,000, as the purchase of the fee is deemed an asset purchase under ASC 805. In April 2017, the Company issued 217,390 shares of common stock and 108,696 warrants, pursuant to a subscription agreement, for the stated consideration and satisfaction of obligation to pay $50,000 on the 180-day anniversary of the execution of this agreement. As of June 30, 2020 and December 31, 2019, the $0 and $0, respectively was included in accounts payable and accrued expenses in regard to this agreement.

During 2018, the Company entered into a license agreement (the “Alphabet Agreement”) with M.ALPHABET, LLC (“Alphabet”), pursuant to which Alphabet agreed to license its PURPUREX business which consists of methods and compositions developed by Alphabet for the treatment of purpura, bruising, post-procedural bruising and traumatic bruising (the “Product Line”). Pursuant to the license granted under the Alphabet Agreement, Conversion Labs PR obtains an exclusive license to incorporate (i) any intellectual property rights related to the Product Line and (ii) all designs, drawings, formulas, chemical compositions and specifications used or useable in the Product Line into one or more products manufactured, sold, and/or distributed by Alphabet for the treatment of purpura, bruising, post-procedural bruising and traumatic bruising and for all other fields of use or purposes (the “Licensed Product(s)”), and to make, have made, advertise, promote, market, sell, import, export, use, offer to sell and distribute the Licensed Product(s) throughout the world with the exception of China, Hong Kong, Japan, and Australia (the “License”).

19

The Company shall pay Alphabet a royalty equal to 13% of Gross Receipts (as defined in the Agreement) realized from the sales of Licensed Products. Further, so long as the Agreement is not previously terminated, the Company, also agreed to pay Alphabet $50,000 on the 120-day anniversary of the Agreement and an additional $50,000 on the 360-day anniversary of the Agreement.

Upon execution of the Alphabet Agreement, Alphabet was granted a 10-year option to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.50. Further, if Licensed Products have gross receipts of $7,500,000 in any calendar year, the Company will grant Alphabet an option to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.50; (ii) if Licensed Products have gross receipts of $10,000,000 in any calendar year, the Company will grant Alphabet an additional option to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.50 and (iii) If Licensed Products have gross receipts of $20,000,000 in any calendar year, the Company will grant Alphabet an option to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.75.

Employment and Consulting Agreements

The Company has entered into various agreements with officers, directors, employees and consultants that expire in one to five years.

Legal Matters

In the normal course of business operations, the Company may become involved in various legal matters. As of June 30, 2020, the Company’s management does not believe that there are any potential legal matters that could have an adverse effect on the Company’s financial position.

NOTE 8 – RELATED PARTY TRANSACTONS

Chief Executive Officer

Conversion Labs PR utilizes office space in Puerto Rico which is subleased from Mr. Schreiber (President and CEO) incurs expense of approximately $4,000 to $5,000 a month for this office space for which the Company and the CEO do not have a written lease agreement. Payments to JLS Ventures, an entity wholly owned by our Chief Executive Officer, Mr. Schreiber, for rent on Conversion Labs PR’s Puerto Rico office space amounted to $15,000 and $12,000 for the three months ended June 30, 2020 and 2019, respectively.

Conversion Labs PR utilizes BV Global Fulfillment, owned by a related person of the Company’s current Chief Executive Officer to warehouse a majority of the Company’s finished goods inventory and for fulfillment services. The Company pays a monthly fee of $13,000 to $16,000 for fulfillment services and reimburses BV Global Fulfillment for their direct costs associated with shipping the Company’s products. As of June 30, 2020 and December 31, 2019, the Company owed BV Global Fulfillment $161,823 and $53,026, respectively, which are included in accounts payable and accrued liabilities on the accompany consolidated balance sheets.

NOTE 9 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date these financial statements were issued and has identified the following:

On July 27, 2020, the Company issued a secured convertible promissory Note in the principal amount of up to $1,500,000, to an accredited investor. The Company received $600,000 in aggregate gross proceeds. Any additional advances under this note would require the approval of the lender in its sole discretion. This note accrues interest at a rate of one and one-quarter percent (1.25%) per month and matures on January 24, 2021. Upon the closing of a Qualified Financing prior to repayment of this note, upon the written election by the investor, the outstanding principal and all accrued but unpaid interest thereon shall convert into fully paid and nonassessable shares of the preferred stock, par value $0.001 per share, of the Company issued and sold by the Company at the closing of a Qualified Financing. Upon such written election by the lender, this note shall convert into the number of shares of preferred stock (including fractional shares) equal to the quotient of (i) the outstanding principal and accrued but unpaid interest on this note, divided by (ii) the price per share paid by the cash purchasers of the preferred stock sold in such Qualified Financing. “Qualified Financing” means a transaction or series of transactions with the principal purpose of raising capital pursuant to which the Company issues and sells shares of preferred stock for aggregate gross proceeds of at least $2,500,000 (excluding all proceeds from the incurrence of indebtedness, including this note, that is converted into such preferred stock, or otherwise cancelled in consideration for the issuance of such preferred stock). As collateral security for the Company’s obligations under this note, the Company pledged, assigned and transferred to the investor a first priority security interest in and collateral assignment of the Company’s right, title and interest in and to all of the Company’s tangible and intangible property. This note contains customary events of default (each an “Event of Default”). If an Event of Default occurs, all outstanding obligations owing under this note will become immediately due and payable at the investor’s election.

During August 2020, the Company offered an inducement to all warrant holders of our $0.40 warrants for a total 2,634,228 common stock warrants outstanding by offering a $0.05 discount on the exercise price of these warrants if they immediately exercised. The adjusted exercise price of these warrants would become $0.35. To date, a vast majority of our warrant holders have exercised this discount, but the Company is still in the process of completing the inducement.

20

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) that reflect management’s current views with respect to future events and financial performance. These statements are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used herein, the words “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company’s business, industry, and the Company’s operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report. The forward-looking statements made in this report are based only on events or information as of the date on which the statements are made in this report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this report and the documents we refer to in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect. These risks include, by way of example and without limitation:

● our ability to successfully commercialize our products on a large enough scale to generate profitable operations;

● our ability to maintain and develop relationships with customers and suppliers;

● our ability to successfully integrate acquired businesses or new brands;

● the impact of competitive products and pricing;

● supply constraints or difficulties;

● general economic and business conditions;

● business interruptions resulting from geo-political actions, including war, and terrorism or disease outbreaks (such as COVID-19);

● our ability to continue as a going concern;

● our need to raise additional funds in the future;

● our ability to successfully recruit and retain qualified personnel;

● our ability to successfully implement our business plan;

● our ability to successfully acquire, develop or commercialize new products and equipment;

● intellectual property claims brought by third parties; and

● the impact of any industry regulation.

21

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, or performance. Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission (“SEC”). We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.

As used in this Quarterly Report on Form 10-Q and unless otherwise indicated, the terms “Company,” “we,” “us,” and “our” refer to Conversion Labs, Inc. (formerly known as Immudyne, Inc.), our wholly owned subsidiary Conversion Labs PR, LLC (formerly Immudyne PR LLC, now “Conversion Labs PR”), a Puerto Rico limited liability company (“Conversion Labs PR”) and our majority-owned subsidiaries LegalSimpli Software, LLC, a Puerto Rico limited liability company (“LegalSimpli”). Unless otherwise specified, all dollar amounts are expressed in United States dollars.

Corporate History

Conversion Labs, Inc., was formed in the State of Delaware on May 24, 1994, under our prior name, Immudyne, Inc. We changed our name to Conversion Labs, Inc. on June 22, 2018. Further, in connection with changing its name, the Company changed its trading symbol to CVLB. On April 1, 2016, our majority-owned subsidiary, Immudyne PR LLC (“Immudyne PR”), which was initially formed for the purpose of a joint venture with the original owners of one of our skincare products, amended and restated its operating agreement whereby we increased our ownership and voting interest in Immudyne PR to 78.2%. Concurrent with the name change of the parent company to Conversion Labs, Inc. completed in 2018, Immudyne PR was renamed to Conversion Labs PR LLC (now known as “Conversion Labs PR”). On April 25, 2019, the operating agreement of Conversion Labs PR was amended and restated in its entirety after acquiring the remaining minority interest in the Conversion Labs PR, which is now a wholly-owned subsidiary of the Company.

In June 2018, Conversion Labs closed the strategic acquisition of 51% of LegalSimpli Software, LLC (“LegalSimpli”), a software as a service (SaaS) for converting, editing, signing and sharing PDF documents. In addition to LegalSimpli’s growth business model, this acquisition added deep search engine optimization and search engine marketing expertise to the Company.

In early 2019, we also launched a service-based business under the name Conversion Labs Media LLC, which was to be used to run e-commerce marketing campaigns for other online businesses. However, this business was discontinued in 2019 in order to focus on our core business as well the expansion of our telehealth opportunities.

In June 2019, a joint venture with GoGoMeds.com was formed allowing us to market branded and generic prescription drugs that are then sold and shipped (via GoGoMeds) online directly to consumers in all 50 states and the District of Columbia.  

Business Overview

The Company is a direct response healthcare company that provides a convenient, cost-effective and smarter way for consumers to access high quality Over The Counter (OTC) products and prescription medications. The U.S. healthcare system is undergoing a paradigm shift largely due to new technologies and the emergence of direct-to-consumer healthcare. We believe the traditional model of visiting a doctor’s office, receiving a physical prescription, visiting a neighborhood pharmacy, and returning to see a doctor for follow up care or prescription refills is inefficient, costly to patients, and discourages many patients from seeking much needed medical care. Direct-to-consumer telemedicine companies, like our Company, offer patients immediate and virtual treatment from licensed physicians, and the home delivery of prescription medications, devices and diagnostics bundled with over-the counter wellness products.

22

We have built a platform that allows us to efficiently launch telehealth and wellness product lines wherever we determine there is a market need. Our platform is supported by a driven team of digital marketing and branding experts, data analysts, designers, and engineers focused on building enduring brands.

Telemedicine Platform

Beginning in 2019, we have made significant investments in our telemedicine technology platform which is the backbone of our physician network, pharmacy provider, CRM system, and third-party advertising platforms. This platform facilitates patient consultations, virtual prescriptions, fulfillment, and follow-up consultations.

Our Telehealth Brands

Our telehealth brands have been built with one singular focus in mind: to become the leading provider of quality healthcare in a virtual setting. To this end, we work with our physicians, our advisors, and our patients to ensure that we can provide the ultimate quality of care. We believe the long-term success of our telehealth business will be driven primarily by the outstanding care we provide in our services and product offerings. Our current brand portfolio is comprised of telehealth brands respectively targeting three market segments: hair loss, men’s health, and emergency medications.

Majority Owned Subsidiary: PDFSimpli

PDFSimpli is a PDF conversion software product, which was acquired through the purchase of 51% of the membership interests of LegalSimpli a Puerto Rico limited liability company, which operates a marketing-driven software solutions business. PDFSimpli enables users to convert, edit and sign PDF documents. As of March 1, 2020, PDFSimpli was ranked in the top 5,750 websites globally, in which it was also ranked in the top 1,200 for specific countries with more than 4.5 million registrants globally.  Since its launch, PDFSimpli has converted or edited over 5 terabytes of documents for customers from the legal, financial, real-estate and academic sectors. PDFSimpli has over 39,000 active subscriptions as of March 1, 2020. 

Impact of COVID-19 Pandemic

We are closely monitoring how the spread of the COVID-19 pandemic caused by the novel coronavirus is affecting our employees, customers and business operations. We have developed preparedness plans to help safeguard the safety of our employees and customers, while safely continuing business operations.

Due to the global spread of the outbreak, the severity of the pandemic in New York, California, and Puerto Rico where we have corporate offices, and in line with guidance from public health officials, we have temporarily restricted access to our offices and implemented a mandatory remote work policy during this period. Our offices will remain closed until we are able to safely and responsibly re-open them in accordance with governmental and public health guidance, as well as health and safety policies tailored to our operations.

As a result of the early measures we took in response to the COVID-19 pandemic to protect our employees and business operations, our business has not been materially negatively impacted during these extraordinary times. We have experienced relatively minor impacts on our inventory availability and delivery capacity since the outbreak, none of which has materially impacted our ability to service our customers. We have taken measures to bolster key aspects of our supply chain to support our continued growth. We continue to work with our existing manufacturing, logistics and other supply chain partners to build key processes to ensure our ability to service our customers.

We are also carefully monitoring shifting consumer behavior from brick and mortar retail and physical healthcare offices to our online platform. We have observed continued strength in our e-commerce sales since the end of the quarter ended June 30, 2020, due in part to changing consumer behavior during the COVID-19 pandemic and widespread awareness and acceptance of telemedicine. Telemedicine businesses, such as ours, have benefitted from increased coverage and visibility due to quarantine measures and policies adopted widely across the country. We believe the increased awareness of telehealth is reflected in the rapid growth we are seeing across our telehealth brands.

23

Results of Operations

Comparison of the Three Months Ended June 30, 2020 to the Three Months Ended June 30, 2019

Revenue

Our financial results for the three months ended June 30, 2020 are summarized as follows in comparison to the three months ended June 30,2019:

	June 30, 2020						June 30, 2019
	$			% of Sales			$			% of Sales
Product revenues, net		7,869,813			87	%		2,307,909			86	%
Software revenues, net		1,219,970			13	%		390,498			14	%
Service revenues, net		-			0	%		-			0	%
Total revenues, net	$	9,089,783			100	%	$	2,698,407			100	%
Cost of product revenue		2,118,001			23	%		589,690			22	%
Cost of software revenue		72,207			1	%		65,521			2	%
Total cost of revenue		2,190,208			24	%		655,211			24	%
Gross profit	$	6,899,575			76	%	$	2,043,196			76	%
Selling & marketing expenses		8,394,331			92	%		2,215,913			82	%
General and administrative expenses		1,338,549			15	%		372,853			14	%
Operating expenses		203,260			2	%		95,477			4	%
Customer service expenses		89,482			1	%		141,278			5	%
Development costs		92,325			1	%		50,838			2	%
Total expenses	$	10,117,947			111	%	$	2,876,360			107	%
Loss from operations	$	(3,218,372	)		(35	)%	$	(833,164	)		(31	)%
Other income (expenses)		(228,875	)		(30	)%		(129,826	)		(5	)%
Income from continuing operations before provision for income taxes	$	(3,447,247	)		(38	)%	$	(962,990	)		(36	)%
Income taxes		-			0	%		-			0	%
Net income (loss) attributable to noncontrolling interests	$	(68,131	)		(1	)%	$	(144,887	)		(5	)%
Net income (loss) attributable to Conversion Labs, Inc.	$	(3,379,116	)		(37	)%	$	(818,103	)		(30	)%

Revenues for the three months ended June 30, 2020 were approximately $9.1 million, an increase of 236.9% compared to approximately $2.3 million for the three months ended June 30, 2019. The increase in revenues was attributable to both the increase in product revenue of 241.0% and an increase in software revenue of 212.4%. Product revenue accounts for 87% of total revenue and has increased in the three months ended June 30, 2020 due to an increase in online sales demands. Management attributes a portion of this increased demand to the nationwide lockdown resulting from COVID-19 precautions and the resulting increase in consumers’ purchases online. Software revenue accounts for 13% of total revenue and has steadily increased quarter over quarter due to a combination of higher demand, market awareness, and continued marketing campaigns.

24

Cost of product revenues consists primarily of product material costs and fulfillment costs directly attributable to the production of our products. Cost of software revenue consist primarily of credit card processing fees and information technology fees related to our online platform. Total cost of revenue increased by approximately 234.3.% to approximately $2.2 million for the three months ended June 30, 2020 compared to approximately $655,000 for the three months ended June 30, 2019. The increase in cost of revenues was due to increased revenues and related increase in merchant and other processing fees incurred due to the higher sales volumes in both our product and software sales.

Gross profit increased by approximately 237.7% to approximately $6.9 million for the three months ended June 30, 2020 compared to approximately $2.0 million for the three months ended June 30, 2019. This is a result of the increased sales. Gross profit as a percentage of revenues remained consistent at 76% for the three months ended June 30, 2020 and for the three months ended June 30, 2019.

Operating Expenses

	Three Months Ended June 30,
	2020		2019
Selling & marketing expenses	$	8,394,331	$	2,215,913
General and administrative expenses		1,338,549		372,853
Operating expenses		203,260		95,477
Customer service expenses		89,482		141,278
Development costs		92,325		50,838
Total operating expenses	$	10,117,947	$	2,876,360

Operating expenses for the three months ended June 30, 2020 were approximately $10.1 million, as compared to approximately $2.9 million for the three months ended June 30, 2019. This represents an increase of 251.8%, or $7.2 million. The increase is primarily attributable to:

(i)	Selling and marketing expenses: This mainly consists of online marketing and advertising expenses. During the three months ended June 30, 2020, the Company had an increase of approximately $5.1 million in selling and marketing costs resulting from additional sales and marketing initiatives to drive further growth throughout all of 2020.
(ii)	General and administrative expenses: This mainly consists of payroll expenses for executive management, stock-based compensation, amortization expense and legal and professional fees. During the three months ended June 30, 2020, the Company has had an increase of approximately $950,000 in general and administrative expenses, primarily related to stock-based compensations and infrastructure to support the increase in sales volume.
(iii)	Other operating expenses: This mainly consists of rent, insurance, royalty expense, bank charges and IT services for our online products. During the three months ended June 30, 2020, the Company had an increase of approximately $100,000, primarily related to increases in sales volume driving up bank charges, IT services, and offices supplies offset by decreases in rent and royalty expense.
(iv)	Customer service expenses: This consists of payroll and benefit expenses related to the Company’s customer service department located in Puerto Rico. During the three months ended June 30, 2020, the Company had a decrease of approximately $51,000, primarily related to decreases in headcount in the Company’s customer service department.
(v)	Development costs: This mainly relates to third-party technology services for developing and maintaining our online platforms. During the three months ended June 30, 2020, the Company had an increase of approximately $41,000, primarily resulting from technology platform improvements for LegalSimpli and amortization expenses at Conversion Labs PR.

25

Other Expense

	Three Months Ended June 30,
	2020		2019
Interest expense	$	228,875	$	129,826
Total	$	228,875	$	129,826

Other expense for the three months ended June 30, 2020 increased by $99,000 compared to the three months ended June 30,2019. The increase in other expense is primarily attributable to an increase in the amortization of debt discount.

Comparison of the Six Months Ended June 30, 2020 to the Six Months Ended June 30, 2019

Revenue

Our financial results for the six months ended June 30, 2020 are summarized as follows in comparison to the six months ended June 30, 2019:

	June 30, 2020						June 30, 2019
	$			% of Sales			$			% of Sales
Product revenues, net		10,825,614			81	%		4,729,435			88	%
Software revenues, net		2,568,981			19	%		667,962			12	%
Service revenues, net		-			0	%		-			0	%
Total revenues, net	$	13,394,595			100	%	$	5,397,397			100	%
Cost of product revenue		3,462,161			26	%		1,199,866			22	%
Cost of software revenue		487,686			4	%		133,318			2	%
Total cost of revenue		3,949,847			29	%		1,333,184			25	%
Gross profit	$	9,444,748			71	%	$	4,064,213			75	%
Selling & marketing expenses		11,140,213			83	%		4,206,894			78	%
General and administrative expenses		2,507,527			19	%		707,859			13	%
Operating expenses		327,751			2	%		181,263			3	%
Customer service expenses		257,667			2	%		268,216			5	%
Development costs		170,467			1	%		96,515			2	%
Total expenses	$	14,403,625			108	%	$	5,460,747			101	%
Loss from operations	$	(4,958,877	)		(46	)%	$	(1,396,534	)		(30	)%
Other income (expenses)		(1,021,914	)		(9	)%		(300,020	)		(6	)%
Income from continuing operations before provision for income taxes	$	(5,980,791	)		(55	)%	$	(1,696,554	)		(36	)%
Income taxes		-			0	%		-			0	%
Net income (loss) attributable to noncontrolling interests	$	(206,947	)		(2	)%	$	(214,702	)		(5	)%
Net income (loss) attributable to Conversion Labs, Inc.	$	(5,773,844	)		(53	)%	$	(1,481,852	)		(31	)%

26

Revenues for the six months ended June 30, 2020 were approximately $13.4 million, an increase of 148.2% compared to approximately $5.4 million for the six months ended June 30, 2019. The increase in revenues was attributable to both the increase in product revenue of 128.9% and an increase in software revenue of 284.6%. Product revenue accounts for 81% of total revenue and has increased in the six months ended June 30, 2020 due to an increase in online sales demands. Management attributes a portion of this increased demand to the nationwide lockdown resulting from COVID-19 precautions and the resulting increase in consumers’ purchases online. Software revenue accounts for 19% of total revenue and has steadily increased quarter over quarter due to a combination of higher demand, market awareness, and continued marketing campaigns.

Cost of product revenues consists primarily of product material costs and fulfillment costs directly attributable to product production. Cost of software revenue consist primarily of credit card processing fees and information technology fees related to our online platform. Total cost of revenue increased by approximately 196.3% to approximately $3.9 million for the six months ended June 30, 2020 compared to approximately $1.3 million for the six months ended June 30,2019. The increase in cost of revenues was due to increased revenues and a related increase in merchant and other processing fees incurred due to the higher sales volumes in both our product and software sales.

Gross profit increased by approximately 132.4% to approximately $9.4 million for the six months ended June 30,2020 compared to approximately $4.1 million for the six months ended June 30, 2019. This is due to increased sales. Gross profit as a percentage of revenues was 71% for the six months ended June 30, 2020 versus 75% for the six months ended June 30, 2019. The decrease of 4% is attributed to the higher cost of sales incurred during the second quarter of 2020 resulting from the use of different suppliers. New suppliers were used to supplement production for increased product demand.

Operating Expenses

	Six Months Ended June 30,
	2020		2019
Selling & marketing expenses	$	11,140,213	$	4,206,894
General and administrative expenses		2,507,527		707,859
Operating expenses		327,751		181,263
Customer service expenses		257,667		268,216
Development costs		170,467		96,515
Total operating expenses	$	14,403,625	$	5,460,747

Operating expenses for the six months ended June 30, 2020 were approximately $14.4 million, as compared to approximately $5.5 million for the six months ended June 30, 2019. This represents an increase of 163.8%, or $8.9 million. The increase is primarily attributable to:

(i)

Selling and marketing expenses: This mainly consists of online marketing and advertising expenses. During the six months ended June 30,2020, the Company had an increase of approximately $7 million in selling and marketing costs. This resulted from additional sales and marketing initiatives to drive further growth throughout all of 2020.

(ii)

General and administrative expenses: This mainly consists of payroll expenses for executive management, stock-based compensation, amortization expense and legal and professional fees. During the six months ended June 30, 2020, the Company has had an increase of approximately $1.8 millions in general and administrative expenses mainly related to stock-based compensations and infrastructure to support the increase in sales volume.

27

(iii)	Other operating expenses: This consists of rent, insurance, royalty expense, bank charges and IT services for our online products. During the six months ended June 30, 2020, the Company had an increase of approximately $146,000, primarily related to increases in sales volume driving up banking fees, IT services, and offices supplies, offset by decreases in rent and royalty expense.
(iv)	Customer service expenses: This mainly consists of payroll and benefit expenses related to the Company’s customer service department located in Puerto Rico. During the six months ended June 30, 2020, the Company had a decrease of approximately $11,000, primarily related to decreases in headcount in the Company’s customer service department effected in the second quarter.
(v)	Development costs: This mainly relates to third-party technology services for developing and maintaining our online platforms. During the six months ended June 30, 2020, the Company had an increase of approximately $41,000, primarily resulting from technology platform improvements for LegalSimpli and amortization expenses at Conversion Labs PR.

	Six Months Ended June 30,
	2020		2019
Interest expense	$	1,021,914	$	300,020
Total	$	1,021,914	$	300,020

Other expense for the six months ended June 30, 2020 increased by $721,894 compared to the six months ended June 30,2019. The increase in other expense is primarily attributable to increases in interest and amortization of debt discount.

Working Capital

	June 30, 2020			December 31, 2019
Current assets	$	2,191,089		$	2,747,402
Current liabilities		7,164,014			3,975,442
Working capital	$	(4,972,925	)	$	(1,228,340	)

Current assets decreased by approximately $556,000 for the six months ended June 30,2020. This is primarily attributable to a decrease in cash and cash equivalents of $770,000 due to payments on convertible notes. This was offset by an increase in accounts receivable and other current assets of $214,000. Current liabilities increased by $3.2 million which was primarily attributable to an increase in accounts payable and accrued liabilities as a result of the Company extending payables and credit terms with vendors during the six months ended June 30, 2020.

Liquidity and Capital Resources

	Six Months Ended
	June 30, 2020			June 30,2019
Net loss	$	(5,980,791	)	$	(1,696,554	)
Net cash provided by operating activities		(1,097,281	)		640,182
Net cash (used in) investing activities		(677,161	)		(500,000	)
Net cash provided by (used in) financing activities		1,003,969			(55,168	)
Net increase (decrease) in cash	$	(770,143	)	$	85,014

Since inception, the Company has funded operations through the revenues of its products, issuance of common stock, receipt of loans and advances from officers and directors and the issuance of convertible notes to third-party investors.

Net cash provided by operating activities was approximately $1.1 million for the six months ended June 30, 2020, as compared with net cash used in operating activities of approximately $640,000 for the six months ended June 30, 2019.

28

Net cash used in investing activities for the six months ended June 30, 2020 was approximately $677,000, as compared with net cash provided by investing activities of $500,000 for the six months ended June 30, 2019. Net cash used in investing activities was primarily due to continued payments on the Company’s purchase of LegalSimpli of $400,000 and the cash paid for capitalized software costs of approximately $277,000.

Net cash provided by financing activities for the six months ended June 30, 2020 was $1,003,969, as compared with net cash used in financing activities of $55,168 for the six months ended June 30, 2019. During the six months ended June 30, 2020, financing activities consisted of proceeds from convertible notes payable $1,750,000, and cash receipts for shares of $1,889,000 which were offset by the repayment of notes payable of approximately $2,500,000, distributions of noncontrolling interests of $121,223 and payment for debt issuance costs of $15,000.

Liquidity and Capital Resources Outlook

The Company has funded operations in the past through the sales of its products, issuance of common stock and through loans and advances from officers and directors. The Company’s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors, obtaining funding from third-party sources or the issuance of additional shares of common stock.

The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2020, the Company has an accumulated deficit approximating $23.7 million and has experienced significant losses from continuing operations. Based on the Company’s cash balance as of June 30, 2020, and projected cash needs, management estimates that it will need an additional $4.0 million through the next 12 months, either from increasing sales revenue and/or raising additional capital via the sale of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company. Based on these circumstances, management has determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Critical Accounting Policies and Estimates

Our significant accounting policies are more fully described in the notes to our financial statements. We believe that the accounting policies below are critical for one to fully understand and evaluate our financial condition and results of operations.

Revenue Recognition

The Company records revenue under the adoption of ASC 606 by analyzing exchanges with its customers using a five-step analysis:

1.	Identify the contract
2.	Identify performance obligations
3.	Determine the transaction price
4.	Allocate the transaction price
5.	Recognize revenue

For the Company’s product-based contracts with customers, the Company has determined that there is one performance obligation and the delivery of this performance obligation is transferred at a point in time. The Company generally records sales of finished products once the customer places and pays for the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer’s delivery site, then recognition of revenue should be deferred until that time, however the Company does not have a process to properly record the recognition of revenue if orders are not immediately shipped. Delivery is considered to have occurred when title and risk of loss have transferred to the customer, which is usually upon shipment of the product. The Company does sell a subscription based service which is based on the recurring shipment of products and billed as if the Company were receiving recurring revenues and orders each month, therefore, the Company records these upon shipment to the customer.

29

The Company records an estimate for provisions of discounts, returns, allowances, customer rebates and other adjustments for each shipment, and are netted with gross sales. The Company’s discounts and customer rebates are known at the time of sale and the Company appropriately debits net product revenues for these transactions based on the known discount and customer rebates. The Company estimates for customer returns and allowances based on estimates of historical transactions and accounts for such provisions during the same period in which the related revenues are earned. The Company has determined that the population of contracts with customers tends to be homogenous, so that review of the contracts and estimate of various revenue related adjustments can be applied to the entire portfolio population.

The Company offers a suite of software to customers as a monthly subscription-based service. This suite of software allows the user or subscriber to convert almost any type of document to other editable document type formats for easy editing. For these subscription-based contracts with customers, the Company offers a 14-day trial period which is billed at $1.95 for an initial period, a monthly subscription, or a yearly subscription to the Company’s software. The Company has estimated that there is one product and performance obligation that is delivered over time, as the Company allows the subscriber to access the service for the time period purchased. The Company allows the customer to cancel at any point during the billing cycle, in which case the customers subscription will not be renewed for the following month or year depending on the original subscription. The Company records the sales over the customers subscription period for monthly and yearly subscribers or at the end of the initial 14 day service period for customers who purchased the initial subscription. The Company offers a discount for purchase of the monthly and yearly subscriptions, which must be paid at the initiation of the contract term, so that the contract price is fixed at the contract initiation. Yearly and monthly subscriptions for the subscription are recorded net of the Company’s known discount. As of the period ended June 30, 2020 and as the year ended December 31, 2019, the Company has accrued contract liabilities of approximately $303,000 and $110,000, respectively which represent obligation on in-process monthly or yearly contracts with customers and yet to be recognized initial 14-day trial periods.

Customer discounts, returns and rebates on product revenues during the six months ended June 30, 2020 and six months ended June 30,2019 approximated $1.3 million and $713,000, respectively. Customer discounts and allowances on software revenues during the three months ended June 30, 2020 and the three months ended June 30, 2019 approximated $163,000 and $26,500, respectively.

Capitalized Software Costs

The Company capitalizes certain payroll and third-party costs related to internally developed software and amortize these costs using the straight-line method over the estimated useful life of the software, generally three years. The Company does not sell internally developed software. Certain development costs not meeting the criteria for capitalization, in accordance with ASC 350-40 Internal-Use Software, are expensed as incurred. As of June 30, 2020 and 2019, the Company capitalized $313,827 and $0 related to internally developed software costs which is included in development. As of June 30,2020, these costs include $40,000 in capitalized stock based compensation that was given to a third-party service provider. During the three months ending June 30, 2020 and 2019, the Company amortized $8,251 and $0 of capitalized software costs.

Intangible Assets

Intangible assets are comprised of customer relationship asset and purchased licenses with estimated useful lives of three years and indefinite lived, respectively. Intangible assets are amortized over their estimated lives using the straight-line method. Costs incurred to renew or extend the term of recognized intangible assets are capitalized and amortized over the useful life of the asset.

30

Income Taxes

The Company files corporate federal and state tax returns. Conversion Labs PR and LegalSimpli file tax returns in Puerto Rico, both are limited liability companies and file separate tax returns with any tax liabilities or benefits passing through to its members.

The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, “Accounting for Income Taxes.” This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company’s tax returns for all years since December 31, 2016, remain open to taxing authorities.

Stock-based Compensation

The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting or service period. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company’s common stock shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.

Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

Recently Issued Accounting Standards

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. We do not expect the implementation of this new pronouncement to have a material impact on our consolidated financial statements.

In July 2017, the FASB issued ASU No. 2017-11, “Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features” (“ASU 2017-11”). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share (“EPS”) reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard was adopted on January 1, 2020 and did not have a material impact on the Company’s financial position, results of operations or cash flows.

31

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As a smaller reporting company, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation and subject to the foregoing, our principal executive officer and principal financial officer concluded that, our disclosure controls and procedures were not effective due to the following material weakness(es) in internal control over financial reporting described below.

● Lack of a functioning audit committee and a lack of a majority of outside directors on the Company’s board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures;

● Inadequate segregation of duties consistent with control objectives;

● Insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines;

● Inadequate security and restricted access to computer systems including a disaster recovery plan;

● Lack of formal written policy for the approval, identification and authorization of related party transactions; and

● No written whistleblower policy.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2020 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

32

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations, except as set forth below. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

ITEM 1A. RISK FACTORS

An investment in the Company’s common stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on March 30, 2020, in addition to other information contained in our reports and in this quarterly report in evaluating the Company and its business before purchasing shares of our common stock. Except as set forth below, there have been no material changes to our risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2019. The Company’s business, operating results and financial condition could be adversely affected due to any of those risks. In addition:

We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.

As our business strategies develop, we must add additional managerial, operational, financial and other personnel. Future growth will impose significant added responsibilities on members of management, including:

● identifying, recruiting, integrating, maintaining, and motivating additional personnel;

● managing our internal development efforts effectively, while complying with our contractual obligations to contractors and other third parties; and

● improving our operational, financial and management controls, reporting systems, and procedures.

Our future financial performance will depend, in part, on our ability to effectively manage any future growth, which might be impacted by the COVID-19 outbreak, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. This lack of long-term experience working together may adversely impact our senior management team’s ability to effectively manage our business and growth.

We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, we may not be able to advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our business initiatives and, accordingly, may not achieve our research, development, and commercialization goals.

We face risks related to health epidemics and other outbreaks, which could significantly disrupt our operations.

Our business and operating results could be adversely impacted by the effects of epidemics, including but not limited to the current COVID-19 pandemic. We are closely monitoring the impact of the COVID-19 global outbreak, although there remains significant uncertainty related to the public health situation globally. Our results of operations could be adversely affected to the extent that such coronavirus or any other epidemic generally harms the global economy.

33

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following paragraphs set forth certain information with respect to all securities sold by the Company during the three months ended June 30, 2020 without registration under the Securities Act:

During the six months ended June 30, 2020, the Company received $1,639,000 in cash from investors which was recorded as a liability to issue shares until such time as the shares were issued.

On May 7, 2020, Brio exercised, on a cashless basis, the Brio Warrants in full resulting in the issuance of 611,666 shares of the Company’s common stock to Brio. Upon Brio’s cashless exercise, the 2019 Brio Warrants are no longer in force or effect and no additional issuances will be due or owing.

The above transactions did not involve any underwriters, underwriting discounts or commissions, or any public offering. The Company relied upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) by virtue of Section 4(a)(2) thereof and/or Regulation D promulgated by the SEC under the Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

		Incorporated by Reference
Exhibit Number	Exhibit Description	Form	Exhibit	Filing Date/Period End Date	Filed Herewith
10.1	Form of Convertible Redeemable Promissory Note	8-K	4.1	5/27/2020
10.2	Alpha 2019 Note Repayment and Warrant Amendment	10-Q	10.3	5/19/2020
10.3	Alpha 2018 Warrant Amendment.	10-Q	10.4	5/19/2020
10.4	Brio 2019 Note Repayment and Warrant Amendment	10-Q	10.5	5/19/2020
10.5	Brio 2018 Warrant Amendment	10-Q	10.6	5/19/2020
10.6	Form of Purchase Agreement	10-Q	10.7	5/19/2020
10.7	Consulting Agreement by and between the Company and Auxo Technology Labs.	10-Q	10.8	5/19/2020
31.1*	Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer.				X
31.2*	Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer.				X
32.1**	Section 1350 Certification of Chief Executive Officer.				X
32.2**	Section 1350 Certification of Chief Financial Officer.				X
101.INS*	XBRL Instance Document				X
101.SCH*	XBRL Taxonomy Extension Schema Document				X
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document				X
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document				X
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document				X
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document				X

** In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.

34

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CONVERSION LABS, INC.

By:	/s/ Justin Schreiber
	Justin Schreiber
	Chief Executive Officer and Chairman of the Board (Principal Executive Officer)
Date:	August 14, 2020

By:	/s/ Juan Manuel Piñeiro Dagnery
	Juan Manuel Piñeiro Dagnery
	Chief Financial Officer (Principal Financial Officer)
Date:	August 14, 2020

35

EX-31.1

Exhibit 31.1

CONVERSION LABS, INC.

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Justin Schreiber, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Conversion Labs, Inc. for the period ended June 30, 2020;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:
	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Justin Schreiber
	Justin Schreiber
	Chief Executive Officer and Chairman of the Board (Principal Executive Officer)
Date:	August 14, 2020

EX-31.2

Exhibit 31.2

CONVERSION LABS, INC.

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Juan Manuel Piñeiro Dagnery, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Conversion Labs, Inc. for the period ended June 30, 2020;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:
	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Juan Manuel Piñeiro Dagnery
	Juan Manuel Piñeiro Dagnery
	Chief Financial Officer (Principal Financial and Accounting Officer)
Date:	August 14, 2020

EX-32.1

Exhibit 32.1

CONVERSION LABS, INC.

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form 10-Q for the period ended June 30, 2020 of Conversion Labs, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

By:	/s/ Justin Schreiber
	Justin Schreiber
	Chief Executive Officer and Chairman of the Board (Principal Executive Officer)
Date:	August 14, 2020

EX-32.2

Exhibit 32.2

CONVERSION LABS, INC.

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form 10-Q for the period ended June 30, 2020 of Conversion Labs, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

By:	/s/ Juan Manuel Piñeiro Dagnery
	Juan Manuel Piñeiro Dagnery
	Chief Financial Officer (Principal Financial and Accounting Officer)
Date:	August 14, 2020

XML

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 14, 2020
Cover [Abstract]
Entity Registrant Name	CONVERSION LABS, INC.
Entity Central Index Key	0000948320
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		71,063,444
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

XML

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current Assets
Cash	$ 336,151	$ 1,106,624
Accounts receivable, net	436,025	97,448
Product deposit	281,143	150,000
Inventory, net	808,846	950,059
Other current assets	328,922	442,971
Total Current Assets	2,191,087	2,747,102
Non-current assets
ROU Asset	19,990	23,625
Capitalized Software, net	305,576
Intangible assets, net	507,646	675,452
Total non-current assets	833,212	699,077
Total Assets	3,024,299	3,446,179
Current Liabilities
Accounts payable and accrued expenses	5,789,399	3,051,156
Notes payable, net	1,070,945	814,734
Contract liabilities	303,670	109,552
Total Current Liabilities	7,164,014	3,975,442
Long-term Liabilities
Lease Liability	28,917	29,978
Contingent consideration on purchase of LegalSimpli	100,000	500,000
Liability to issue common stock	540,972
Deferred tax liability	70,000	70,000
Total Liabilities	7,903,903	4,575,420
Stockholders’ Equity (Deficit)
Common stock, $0.01 par value; 100,000,000 shares authorized, 71,063,440 and 53,404,045 shares issued, 70,548,248 and 52,888,845 outstanding as of June 30, 2020 and December 31, 2019, respectively	710,631	534,037
Additional paid-in capital	18,747,862	15,236,396
Accumulated (deficit)	(23,705,170)	(16,594,917)
Equity	(4,246,675)	(824,484)
Treasury stock, 515,200 and 515,200 shares, at cost	(163,701)	(163,701)
Total Conversion Labs, Inc. Stockholders’ (Deficit)	(4,410,376)	(988,185)
Non-controlling interest	(469,226)	(141,056)
Total Stockholders’ (Deficit)	(4,879,602)	(1,129,241)
Total Liabilities and Stockholders’ (Deficit)	$ 3,024,299	$ 3,446,179

XML

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	71,063,440	53,404,045
Common stock, shares outstanding	70,548,248	52,888,845
Treasury stock, shares	515,200	515,200

XML

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Total revenues, net	$ 9,089,783	$ 2,698,407	$ 13,394,595	$ 5,397,397
Cost of revenues	2,190,208	655,211	3,949,847	1,333,184
Gross Profit	6,899,575	2,043,196	9,444,748	4,064,213
Expenses
Selling & marketing expenses	8,394,331	2,215,913	11,140,213	4,206,894
General and administrative expenses	1,338,549	372,853	2,507,527	707,859
Operating expenses	203,260	95,477	327,751	181,263
Customer service expenses	89,482	141,278	257,667	268,216
Development Costs	92,325	50,838	170,467	96,515
Total expenses	10,117,947	2,876,360	14,403,625	5,460,747
Operating Loss	(3,218,372)	(833,164)	(4,958,877)	(1,396,534)
Interest (expense), net	(228,875)	(129,826)	(1,021,914)	(300,020)
Loss from continuing operations before provision for income taxes	(3,447,247)	(962,990)	(5,980,791)	(1,696,554)
Income taxes (Benefit)
Net Income (Loss)	(3,447,247)	(962,990)	(5,980,791)	(1,696,554)
Net (loss) income attributable to noncontrolling interests	(68,131)	(144,887)	(206,947)	(214,702)
Net Income (loss) attributable to Conversion Labs, Inc.	$ (3,379,116)	$ (818,103)	$ (5,773,844)	$ (1,481,852)
Basic loss per share attributable to Conversion Labs, Inc. from continuing operation	$ (0.06)	$ (0.02)	$ (0.10)	$ (0.04)
Diluted loss per share attributable to Conversion Labs, Inc. from continuing operation	$ (0.06)	$ (0.02)	$ (0.10)	$ (0.04)
Weighted Average number of common shares outstanding
Basic	61,743,697	46,882,305	57,616,266	46,844,736
Diluted	61,743,697	46,882,305	57,616,266	46,844,736
Product Revenues, Net [Member]
Total revenues, net	$ 7,869,813	$ 2,307,909	$ 10,825,614	$ 4,729,435
Cost of revenues	2,118,001	589,690	3,462,161	1,199,866
Software Revenues, Net [Member]
Total revenues, net	1,219,970	390,498	2,568,981	667,962
Cost of revenues	72,207	65,521	487,686	133,318
Service Revenues, Net [Member]
Total revenues, net

XML

Condensed Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated (Deficit) [Member]	Treasury Stock [Member]	Conversion Labs, Inc. Stockholders' (Deficit) [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2018	$ 457,822	$ 12,744,249	$ (12,140,670)	$ (163,701)	$ 897,700	$ (77,962)	$ 819,738
Balance, shares at Dec. 31, 2018	45,782,305
Stock issued for services	$ 1,000	15,000			16,000		16,000
Stock issued for services, shares	100,000
Stock compensation	$ 10,000	144,600			154,600		154,600
Stock compensation, shares	1,000,000
Distribution to non-controlling interest						(34,298)	(34,298)
Net (loss)			(663,747)		(663,747)	(69,816)	(733,563)
Balance at Mar. 31, 2019	$ 468,822	12,903,849	(12,804,418)	(163,701)	404,552	(182,075)	222,477
Balance, shares at Mar. 31, 2019	46,882,305
Balance at Dec. 31, 2018	$ 457,822	12,744,249	(12,140,670)	(163,701)	897,700	(77,962)	819,738
Balance, shares at Dec. 31, 2018	45,782,305
Stock compensation							373,000
Net (loss)							(1,696,554)
Balance at Jun. 30, 2019	$ 468,822	13,122,309	(14,941,929)	(163,701)	(1,514,499)	85,416	(1,429,083)
Balance, shares at Jun. 30, 2019	46,882,305
Balance at Mar. 31, 2019	$ 468,822	12,903,849	(12,804,418)	(163,701)	404,552	(182,075)	222,477
Balance, shares at Mar. 31, 2019	46,882,305
Stock compensation		218,460			218,460		218,460
Agreement to issue shares for non-controlling interest in CVLB PR			(1,319,407)		(1,319,407)	412,377	(907,030)
Net (loss)			(818,104)		(818,104)	(144,886)	(962,990)
Balance at Jun. 30, 2019	$ 468,822	13,122,309	(14,941,929)	(163,701)	(1,514,499)	85,416	(1,429,083)
Balance, shares at Jun. 30, 2019	46,882,305
Balance at Dec. 31, 2019	$ 534,037	15,236,396	(16,594,919)	(163,701)	(988,187)	(141,056)	(1,129,241)
Balance, shares at Dec. 31, 2019	53,403,649
Stock compensation		95,900			95,900		95,900
Distribution to non-controlling interest						(36,000)	(36,000)
Cashless exercise of warrants	$ 7,389	(7,389)
Cashless exercise of warrants, shares	739,291
Deemed distribution from down-round provision in common stock shares yet to be issued			(106,519)		(106,519)		(106,519)
Deemed distribution from warrant price adjustments		1,142,385	(1,142,385)
Net (loss)			(2,394,728)		(2,394,728)	(138,816)	(2,533,544)
Balance at Mar. 31, 2020	$ 541,426	16,467,292	(20,238,551)	(163,701)	(3,393,534)	(315,872)	(3,709,406)
Balance, shares at Mar. 31, 2020	54,142,940
Balance at Dec. 31, 2019	$ 534,037	15,236,396	(16,594,919)	(163,701)	(988,187)	(141,056)	(1,129,241)
Balance, shares at Dec. 31, 2019	53,403,649
Stock compensation							535,000
Net (loss)							(5,980,791)
Balance at Jun. 30, 2020	$ 710,631	18,747,862	(23,705,170)	(163,701)	(4,410,378)	(469,226)	(4,879,602)
Balance, shares at Jun. 30, 2020	71,063,440
Balance at Mar. 31, 2020	$ 541,426	16,467,292	(20,238,551)	(163,701)	(3,393,534)	(315,872)	(3,709,406)
Balance, shares at Mar. 31, 2020	54,142,940
Stock issued for services	$ 2,500	32,700			35,200		35,200
Stock issued for services, shares	250,000
Stock compensation		438,575			438,575		438,575
Distribution to non-controlling interest						(85,223)	(85,223)
Cashless exercise of warrants	$ 42,162	(42,162)
Cashless exercise of warrants, shares	4,216,200
Deemed distribution from down-round provision in common stock shares yet to be issued			(87,503)		(87,503)		(87,503)
Purchase of common stock	$ 14,706	235,294			250,000		250,000
Purchase of common stock, shares	1,470,600
Shares issued for share liability	$ 109,837	1,616,163			1,726,000		1,726,000
Shares issued for share liability, shares	10,983,700
Net (loss)			(3,379,116)		(3,379,116)	(68,131)	(3,447,247)
Balance at Jun. 30, 2020	$ 710,631	$ 18,747,862	$ (23,705,170)	$ (163,701)	$ (4,410,378)	$ (469,226)	$ (4,879,602)
Balance, shares at Jun. 30, 2020	71,063,440

XML

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss) income	$ (5,980,791)	$ (1,696,554)
Adjustments to reconcile net (loss) income to net cash provided by (used) in operating activities
Amortization of debt discount	739,324	86,268
Amortization of capitalized software	11,585
Amortization of intangibles	167,806	167,807
Acceleration of debt discount	500,145
Operating Lease Payments	2,574	3,453
Liability to issue shares for services	32,500	242,969
Stock issued for services	35,200	16,000
Stock compensation expense	534,475	373,060
Changes in Assets and Liabilities
Accounts receivable	(338,577)	(4,218)
Product deposit	(131,143)	(98,275)
Inventory	141,213	319,330
Other current assets	114,047	144,241
Deferred revenue	194,118	(3,871)
Deferred tax liability		(4,000)
Accounts payable and accrued expenses	2,880,243	1,113,972
Net cash (used in) provided by operating activities	(1,097,281)	640,182
CASH FLOWS FROM INVESTING ACTIVITIES
Payment to seller for contingent consideration	(277,161)	(500,000)
Proceeds from sale of legacy business	(400,000)
Net cash used in investing activities	(677,161)	(500,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Shares issued for cash	250,000
Cash receipts from investors for unissued shares	1,639,000
Debt issuance costs	(15,000)
Distributions to non-controlling interest	(121,223)	(34,298)
Proceeds from notes payable	1,750,000	50,000
Repayment of notes payable	(2,498,808)	(70,870)
Net cash provided by (used in) financing activities	1,003,969	(55,168)
Net increase in cash	(770,473)	85,014
Cash at beginning of the period	1,106,624	180,093
Cash at end of the period	336,151	265,107
Supplemental Disclosure of Cash Flow Information
Cash paid during the period for interest	4,383	4,383
Agreement to issue shares for non-controlling interest in CVLB PR		907,031
Cashless exercise of warrants	49,551
Deemed distribution from down-round provision	1,142,385
Stock yet to be issued for capitalized costs	40,000
Deemed distribution from down-round provision on unissued shares	194,022
Shares issued for share liability	(1,726,000)
Debt issuance costs for liability to issue shares	$ 219,450

XML

Nature of the Organization and Business

6 Months Ended

Jun. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of the Organization and Business

NOTE 1 – NATURE OF THE ORGANIZATION AND BUSINESS

Nature of Business

Conversion Labs, Inc., was formed in the State of Delaware on May 24, 1994, under our prior name, Immudyne, Inc. We changed our name to Conversion Labs, Inc. on June 22, 2018. Further, in connection with changing its name, the Company changed its trading symbol to CVLB. On April 1, 2016, our majority-owned subsidiary, Immudyne PR LLC (“Immudyne PR”), which was initially formed for the purpose of a joint venture with the original owners of one of our skincare products, amended and restated its operating agreement whereby we increased our ownership and voting interest in Immudyne PR to 78.2%. Concurrent with the name change of the parent company to Conversion Labs, Inc. completed in 2018, Immudyne PR was renamed to Conversion Labs PR LLC (now known as “Conversion Labs PR”). On April 25, 2019, the operating agreement of Conversion Labs PR was amended and restated in its entirety after acquiring the remaining minority interest in the Conversion Labs PR, which is now a wholly-owned subsidiary of the Company.

In June 2018, Conversion Labs closed the strategic acquisition of 51% of LegalSimpli Software, LLC, a software as a service (SaaS) application for converting, editing, signing and sharing PDF documents. In addition to LegalSimpli Software’s growth business model, this acquisition added deep search engine optimization and search engine marketing expertise to the Company.

In early 2019, the Company also launched a service-based business under the name Conversion Labs Media LLC, which was to be used to run e-commerce marketing campaigns for other online businesses. However, this business was discontinued in 2019 in order to focus on its core business as well the expansion of our telehealth opportunities.

In June 2019, a strategic joint venture with GoGoMeds.com (GoGoMeds) was formed in order to help facilitate the launch of our telemedicine business. GoGoMeds is a nationwide pharmacy licensed to dispense prescription medications directly to consumers in all 50 states and the District of Columbia.

The Company is a direct to consumer response healthcare company that provides a convenient, cost-effective and smarter way for consumers to access high quality Over The Counter (OTC) products and prescription medications. The U.S. healthcare system is undergoing a paradigm shift largely due to new technologies and the emergence of direct-to-consumer healthcare. We believe the traditional model of visiting a doctor’s office, receiving a physical prescription, visiting a neighborhood pharmacy, and returning to see a doctor for follow up care or prescription refills is inefficient, costly to patients, and discourages many patients from seeking much needed medical care. Direct-to-consumer telemedicine companies, like our Company, offer patients immediate and virtual treatment from licensed physicians, and the home delivery of prescription medications, devices and diagnostics bundled with over-the counter wellness products.

We have built a platform that allows us to efficiently launch telehealth and wellness product lines wherever we determine there is a market need. Our platform is supported by a driven team of digital marketing and branding experts, data analysts, designers, and engineers focused on building enduring brands.

Unless otherwise indicated, the “Company” refers Conversion Labs, Inc. (formerly known as Immudyne, Inc.), our wholly subsidiary Conversion Labs PR, LLC (formerly Immudyne PR LLC, now “Conversion Labs PR”), a Puerto Rico limited liability company (“Conversion Labs PR”) and our majority-owned subsidiaries LegalSimpli Software, LLC, a Puerto Rico limited liability company (“LegalSimpli”), and Conversion Labs PR, LLC (formerly Immudyne PR LLC, now “Conversion Labs PR”), a Puerto Rico limited liability company (“Conversion Labs PR”). Unless otherwise specified, all dollar amounts are expressed in United States dollars.

Liquidity

The Company has funded operations in the past through the sales of its products, issuance of common stock and through loans and advances from officers and directors. The Company’s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors, obtaining funding from third-party sources or the issuance of additional shares of common stock.

The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2020, the Company has an accumulated deficit approximating $23.7 million and has experienced significant losses from continuing operations. Based on the Company’s cash balance as of June 30, 2020, and projected cash needs, management estimates that it will need an additional $4.0 million through the next 12 months, either from increasing sales revenue and/or raising additional capital via the sale of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company. Based on these circumstances, management has determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”).

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Conversion Labs PR and its majority owned subsidiary, LegalSimpli. The non-controlling interest in LegalSimpli represents the 49% equity interest held by other members of the subsidiary. All significant consolidated transactions and balances have been eliminated in consolidation.

Use of Estimates

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the determination of reserves (if necessary) for accounts receivable, returns and allowances, useful life of intangible and right of use assets, the valuation of inventory and inputs into the provision for lease liabilities and stockholders’ equity-based transactions. Actual results could differ from those estimates.

Reclassifications

Certain reclassifications have been made to conform the prior year’s data to the current presentation. These reclassifications have no effect on previously reported operations, stockholders’ equity (deficit) or cash flows. Given the increase in the Company’s software business and to conform the Company’s presentation of operating results to industry standards, the Company has changed their categories for reporting operations, as result the Company has made reclassifications to the prior year presentation in order to conform it to the current presentation.

Revenue Recognition

The Company records revenue under the adoption of ASC 606 by analyzing exchanges with its customers using a five-step analysis:

1.	Identify the contract
2.	Identify performance obligations
3.	Determine the transaction price
4.	Allocate the transaction price
5.	Recognize revenue

For the Company’s product-based contracts with customers, the Company has determined that there is one performance obligation and the delivery of this performance obligation is transferred at a point in time. The Company generally records sales of finished products once the customer places and pays for the order and the product is simultaneously shipped by a third-party fulfillment service provider, but in limited cases if title does not pass until the product reaches the customer’s delivery site, then recognition of revenue should be deferred until that time, however the Company does not have a process to properly record the recognition of revenue if orders are not immediately shipped. Delivery is considered to have occurred when title and risk of loss have transferred to the customer, which is usually upon shipment of the product. The Company does sell a subscription based service which is based on the recurring shipment of products and billed as if the Company were receiving recurring revenues and orders each month, therefore, the Company records these upon each shipment to the customer.

The Company records an estimate for provisions of discounts, returns, allowances, customer rebates and other adjustments for each shipment, and are netted with gross sales. The Company’s discounts and customer rebates are known at the time of sale and the Company appropriately debits net product revenues for these transactions based on the known discount and customer rebates. The Company estimates for customer returns and allowances based on estimates of historical transactions and accounts for such provisions during the same period in which the related revenues are earned. The Company has determined that the population of contracts with customers tends to be homogenous, so that review of the contracts and estimate of various revenue related adjustments can be applied to the entire portfolio population. Customer discounts, returns and rebates on product revenues during the three months ended June 30, 2020 and 2019 approximated $857,000 and $161,000, respectively. Customer discounts, returns and rebates on product revenues during the six months ended June 30, 2020 and 2019 approximated $1,334,000 and $713,000, respectively. 

The Company began testing trial offers with the Shapiro MD products in late 2018. The Company was unable to adequately implement a process to report any trial-based sales and the related impact on inventory. Given the relatively new trail period being offered, the Company has not been able to estimate the historical effect to determine how this will change the recording of revenue or expected reserve for return rates.

The Company, through its majority-owned subsidiary LegalSimpli, offers a suite of software to customers as a monthly subscription based service. This suite of software allows the user or subscriber to convert almost any type of document to other editable document type formats for easy editing. For these subscription-based contracts with customers, the Company offers a 14-day trial period which is billed at $1.95 for an initial period, a monthly subscription, or a yearly subscription to the Company’s software. The Company has estimated that there is one product and performance obligation that is delivered over time, as the Company allows the subscriber to access the service for the time period purchased. The Company allows the customer to cancel at any point during the billing cycle, in which case the customers subscription will not be renewed for the following month or year depending on the original subscription. The Company records the sales over the customers subscription period for monthly and yearly subscribers or at the end of the initial 14 day service period for customers who purchased the initial subscription. The Company offers a discount for the purchase of the monthly and yearly subscriptions, which must be paid at the initiation of the contract term, so that the Contract price is fixed at the contract initiation. Yearly and monthly subscriptions for the subscription are recorded net of the Company’s known discount rates. As of June 30, 2020 and December 31, 2019, the Company has accrued contract liabilities of approximately $304,000 and $110,000, respectively, which represent obligations on in-process monthly or yearly contracts with customers and yet to be recognized initial 14-day trial periods.

For the six months ended June 30, 2020 and 2019, the Company had the following disaggregated revenue :

	Six Months Ended June 30,
	2020		%			2019		%
Product revenues by Brand for Conversion Labs PR:
Shapiro MD	$	8,156,378		61	%	$	4,413,157		82	%
Rex MD		2,515,560		19	%		-		-
iNR Wellness		119,254		1	%		233,594		4	%
Purpurex		30,317		0	%		10,232		0	%
Scarology		4,105		0	%		18,726		0	%
Innate		0		0	%		4,081		0	%
Total product revenue for Conversion Labs PR	$	10,825,614		81	%	$	4,679,790		86	%
Software revenue for LegalSimpli		2,568,981		19	%		717,607		14	%
Total net revenue	$	13,394,595		100	%	$	5,397,397		100	%

Accounts Receivable

Accounts receivable are carried at original sales amount less an estimate made for returns, chargebacks, and discounts. Accounts receivables mainly consist of receivables from third-party merchant processors which are settled with a couple of days. Management determines the need, if any, for an allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers’ accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. As of June 30, 2020 and 2019, the Company had determined that an allowance for doubtful accounts reserve was not necessary. As of June 30, 2020 and December 31, 2019, the reserve for sales returns and allowances was approximately $351,000 and $82,000, respectively.

Inventory

As of June 30, 2020 and December 31, 2019, inventory consisted primarily of finished cosmetic products. Inventory is maintained at the Company’s third-party warehouse location, which is owned by a related party, in Pennsylvania and at Amazon fulfillment centers.

Inventory is valued at the lower of cost or net realizable value with cost determined on a first-in, first-out (“FIFO”) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to net realizable, if lower. As of June 30, 2020 and December 31, 2019, the Company recorded an inventory reserve in the amount of $34,657 and $12,500, respectively. The increase in our inventory reserve mainly is attributable to the lack of marketability for our INR Wellness product line. As of June 30, 2020 and December 31, 2019, the Company’s inventory consisted of the following:

	June 30, 2020		December 31, 2019
Raw materials and packaging components	$	291,033	$	37,542
Finished products		517,813		912,517
Total net inventory	$	808,846	$	950,059

Product Deposit

Many of our vendors require deposits when a purchase order is placed for goods or fulfillment services. These deposits typically ranging from 10% to 33% of the total purchased amount. Our vendors issue a credit memo when sending their final invoice, reducing the amount the Company owes for the deposit amount previously paid to the vendors. The Company capitalizes these product deposits until the inventory is received at the Company’s fulfillment centers. As of June 30, 2020 and December 31, 2019, the Company has approximately $281,000 and $150,000, respectively, of product deposits with multiple vendors for the purchase of raw materials or finished for products we sell online. As of June 30, 2020 and December 31, 2019, the vast majority of these product deposits are with one vendor that manufacturers the Company’s finished goods inventory for its Shapiro hair care product line.

Capitalized Software Costs

The Company capitalizes certain payroll and third-party costs related to internally developed software and amortize these costs using the straight-line method over the estimated useful life of the software, generally two years. The Company does not sell internally developed software other than through the use of subscription service. Certain development costs not meeting the criteria for capitalization, in accordance with Accounting Standards Codification (“ASC”) ASC 350-40 Internal-Use Software, are expensed as incurred. As of June 30, 2020 and 2019, the Company capitalized $317,160 and $0 related to internally developed software costs which is included in development. As of June 30, 2020, these costs include $40,000 in capitalized stock based compensation that was given to a third-party service provider. During the three months ending June 30, 2020 and 2019, the Company amortized $11,585 and $0 of capitalized software costs, respectively.

Intangible Assets

Intangible assets are comprised of customer relationship asset and purchased licenses with estimated useful lives of three years and indefinite lived, respectively. Intangible assets are amortized over their estimated lives using the straight-line method. Costs incurred to renew or extend the term of recognized intangible assets are capitalized and amortized over the useful life of the asset.

Impairment of Long-Lived Assets

Long-lived assets are evaluated for impairment whenever events or changes in circumstances have indicated that an asset may not be recoverable and are grouped with other assets to the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities (asset group). If the sum of the projected undiscounted cash flows (excluding interest charges) of an asset group is less than its carrying value and the fair value of an asset group is also less than its carrying value, the assets will be written down by the amount by which the carrying value of the asset group exceeded its fair value. However, the carrying amount of a finite-lived intangible asset can never be written down below its fair value. Any loss would be recognized in income from continuing operations in the period in which the determination is made.

Liability to Issue Common Stock

Liability to issue common stock represents liabilities of the Company for failing to issue shares of common stock timely to various consultants and or third-party investors in conjunction with various consulting, service, warrant or stock purchase agreements. As of June 30, 2020, the Company has a liability to issue 2,627,635 shares of common stock for $541,972 in fair value. During the six months ended June 30, 3020, the Company received $1,639,000 in cash from investors which was recorded as a liability to issue shares until such time as the shares were issued. The yet to be issued shares of common stock are valued based on the fair market value of the common stock price on the date of agreement or the purchase price specified in the stock purchase agreement.

Income Taxes

The Company files corporate federal and state tax returns. Conversion Labs PR and LegalSimpli file tax returns in Puerto Rico, both are limited liability companies and file separate tax returns with any tax liabilities or benefits passing through to its members.

The Company records current and deferred taxes in accordance with Accounting Standards Codification (“ASC”) 740, “Accounting for Income Taxes.” This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company’s tax returns for all years since December 31, 2016, remain open to taxing authorities.

Stock-Based Compensation

The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting or service period. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company’s common stock shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.

Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

Earnings (Loss) Per Share

Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.

Common stock equivalents comprising shares underlying 17,498,953 options and warrants for the three and six months ended June 30, 2020 have not been included in the loss per share calculations as the effects are anti-dilutive.

Fair Value of Financial Instruments

The carrying value of the Company’s financial instruments, including cash, accounts receivable, accounts payable and accrued expenses and the face amount of notes payable approximate fair value for all periods.

Concentrations of Risk

The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.

The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.

We are dependent on certain third-party manufacturers, although we believe that other contract manufacturers could be quickly secured if any of our current manufacturers cease to perform adequately. As of June 30, 2020 and December 31, 2019, we utilized two (2) suppliers for fulfillment services, two (2) suppliers for manufacturing finished goods, one (1) supplier for packaging and bottles and one (1) supplier for labeling. For the three and six months ended June 30, 2020 and the year ended December 31, 2019, we purchased 100% of our finished goods from two (2) manufacturers.

Recently Adopted Accounting Pronouncements

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. We do not expect the implementation of this new pronouncement to have a material impact on our consolidated financial statements.

In July 2017, the FASB issued ASU No. 2017-11, “Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features” (“ASU 2017-11”). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share (“EPS”) reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard was adopted on January 1, 2020 and did not have a material impact on the Company’s financial position, results of operations or cash flows.

Recent Accounting Pronouncements

All other accounting standards updates that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

XML

Intangible Assets

6 Months Ended

Jun. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

NOTE 3 – INTANGIBLE ASSETS

As of June 30, 2020, the Company has the following amounts related to intangible assets:

	Gross Carrying Amount		Accumulated Amortization
Amortizable intangible assets
Customer relationship asset	$	1,006,840	$	(699,194	)
Indefinite lived intangible assets
Purchased licenses		200,000		-
	$	1,206,840	$	(699,194	)

As of December 31, 2019 the Company has the following amounts related to intangible assets:

	Gross Carrying Amount		Accumulated Amortization
Amortizable intangible assets:
Customer relationship asset	$	1,006,840	$	(531,388	)
Indefinite lived intangible assets:
Purchased licenses		200,000		-
	$	1,206,840	$	(531,388	)

The aggregate amortization expense of the Company’s intangible assets for the three months ended June 30, 2020 and 2019 was approximately $83,903 and $83,903, respectively. The aggregate amortization expense of the Company’s intangible assets for the six months ended June 30, 2020 and 2019 was approximately $167,806 and $167,806, respectively. Estimated amortization expense for 2020 and 2021 is approximately $336,000 and $140,000, respectively.

XML

Notes Payable

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Notes Payable

NOTE 4 – NOTES PAYABLE

On May 29, 2018, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Alpha Capital Anstalt (“Alpha”) and Brio Capital Master Fund Ltd. (“Brio”). Pursuant to the terms of the Purchase Agreement, the Company issued and sold to them senior secured convertible notes in the aggregate original principal amount of $550,000 (collectively, the “Alpha and Brio Notes”), and warrants to purchase up to 2,391,305 shares of the Company’s common stock (collectively the “Alpha and Brio Warrants”). The Alpha and Brio Notes matured on May 2019. Interest on the outstanding principal amount of the Alpha and Brio Notes compounded annually at the annual rate of twelve percent (12%), subject to adjustments. The Alpha and Brio Notes are convertible into the Company’s common stock, at the option of the holder, at any time following issuance, unless the conversion or share issuance under the conversion would cause the holder to beneficially own in excess of 4.99% of the Company’s common stock. The conversion price for the principal and interest, if any, in connection with voluntary conversion by the Holder shall be $0.23 per share of Common Stock, subject to adjustment as defined in the Alpha and Brio Notes. Alpha and Brio have converted $344,642 of these notes including $9,922 of interest as of December 31, 2019 and 2018. As of June 30, 2020, these notes have been paid off.

On August 15, 2019, the Company entered into securities purchase agreements (the “August Purchase Agreements”) with three accredited investors, including Alpha and Brio. Pursuant to the terms of the August Purchase Agreements, the Company issued and sold to the investors convertible promissory notes for the aggregate original principal amount of $1,291,500 (collectively the “August 2019 Notes”), and warrants to purchase up to 4,679,348   shares of the Company’s common stock (the “August 2019 Warrants”). The August 2019 Notes mature on August 15, 2020 and accrue interest at a rate of twelve percent (12%) per annum, subject to adjustments as defined therein. The August 2019 Notes may be converted into shares of the Company’s common stock, at the discretion of the holder, at any time following issuance, unless the conversion or share issuance under the conversion would cause the holder to beneficially own shares in excess of 4.99% of the Company’s common stock. The conversion price for the principal and interest, if any, in connection with voluntary conversion by the investors shall be $0.23 per share of common stock, subject to adjustment as defined therein. In conjunction with the August 2019 Notes, the Company issued the August 2019 Warrants with an exercise price of $0.28 per share. The fair value of August 2019 Warrants was determined to be $569,147 based on using the Black-Scholes pricing model. The August 2019 Warrants were evaluated by management and deemed to be equity-linked awards subject to ASC 810, Derivatives and Hedging. The August 2019 Notes contained an original issue discount of 20% or $215,250 which is the difference between the note face amount of $1,291,500 and the cash proceeds received from the investors. As part of this financing, the Company paid debt issuance costs $284,070 which are placed as a contra-debt account and amortized over the life of the loan.

On February 25, 2020, the Company entered into a Note Repayment and Warrant Amendment Agreement with Alpha and Brio, whereby the Company agreed to repay the outstanding balance of Alpha and Brio’s August 2019 Notes in the amount of $1,291,000, including principal and interest. As a result of this transaction, the Company accelerated debt discounts for warrants, issuance costs and original issue discount of $500,145, which was recognized through interest expense on the accompanying consolidated statement of operations. As of June 30, 2020 and December 31, 2019, the gross balance payable for these notes was $0 and $1,291,000, respectively. As of June 30, 2020 and December 31, 2019, the Company has cumulatively amortized $568,322 and $404,393 of the debt discounts costs including debt issuance costs, original issue discount, and discount for warrants issued in connection with the debt transaction, all of which is included in interest expense on the accompanying consolidated statement of operations. As of June 30, 2020 and December 31, 2019, the net balance payable for these notes was $0 and $627,426, respectively.  

On February 18, 2020, the Company entered into two purchase agreements (the “C6 Purchase Agreements”) for the purchase and sale of future revenue with C6 Capital, LLC (“C6”). Pursuant to the terms of the C6 Purchase Agreements, the Company issued and sold to C6 two loan agreements   in the aggregate original principal amount of $1,020,000. These loans contain an original purchase discount of 18%, or $270,000, in total, or $135,000 per agreement. C6 paid $375,000 per loan agreement for a total of $750,000. The Company paid debt issuance costs to C6 of $7,500 per agreement, or $15,000 in total, which was placed as a contra-debt account and will be amortized over the life of the loan. The loan agreements require the Company to pay all future receipts of the Company without recourse until such time as the purchased amount has been repaid. The loan agreements require the Company to make a daily average payment of $8,094 during the term of such agreements. As of June 30, 2020, the Company has made $161,904 in principal payments under these loan agreements. As of June 30, 2020, the gross balance payable for these loan agreements was $858,000, and the balance of the loan net of discounts was $600,424. For the three months ended March 31, 2020, the Company has amortized $27,329 of debt discount through interest expense on the accompanying statement of operations.

Beginning May 21, 2020 through May 27, 2020 the Company, issued convertible promissory notes (the “May 2020 Notes”) to six (6) accredited investors (each a “May 2020 Investor”, and collectively, the “May 2020 Investors”). The aggregate principal amount of the May 2020 Notes is $1,000,000 for which the Company received gross proceeds of $1,000,000. The May 2020 Notes are due and payable six months from the date of issuance. The May 2020 Notes entitle each holder to 12% interest upon Maturity. The May 2020 Notes may be converted into shares of the Company’s common stock at any time following the date of issuance at a conversion price of $0.50 per share, subject to adjustment.

As an inducement to enter into the transaction, the Company issued an aggregate of 665,000 shares of the Company’s restricted common stock to the May 2020 Investors. In the event of a default the outstanding balance of the May 2020 Notes shall increase to 130% and shall become immediately due and payable upon notice to the Company.

Total interest expense on notes payable, inclusive of amortization of debt discounts, amounted to $1,021,914 and $300,000 for the six months ended June 30, 2020 and 2019, respectively. Total interest expense on notes payable, inclusive of amortization of debt discounts, amounted to $228,875 and $129,826 for the three months ended June 30, 2020 and 2019, respectively.

In June 2020, the Company and its subsidiaries received loans in the aggregate amount of approximately $242,000 (the “PPP Loan”) under the new Paycheck Protection Program legislation administered by the U.S. Small Business Administration. These loans bear interest at one percent per annum (1.0%) and mature five years from the date of the first disbursement. The proceeds of the PPP Loan must be used for payroll costs, lease payments on agreements before February 15, 2020 and utility payments under agreements before February 1, 2020. At least 60% of the proceeds must be used for payroll costs and certain other expenses and no more than 40% may be used on non-payroll expenses. Proceeds from the PPP Loan used by the Company for the approved expense categories may be fully forgiven by the Small Business Administration if the Company satisfies applicable employee headcount and compensation requirements. The Company currently believes that a majority of the PPP Loan proceeds will qualify for debt forgiveness; however, there can be no assurance that the Company will qualify for forgiveness from the Small Business Administration until it occurs.

XML

Stockholders' Equity

6 Months Ended

Jun. 30, 2020

Stockholders' Equity Note [Abstract]

Stockholders' Equity

NOTE 5 – STOCKHOLDERS’ EQUITY

Common Stock

During the month of February 2020, the Company entered into a stock purchase agreement with a third-party investor for the purchase of 4,000,000 shares of common stock at $0.16 per share for $640,000 in cash consideration.

During the month of March 2020, the entered into a stock purchase agreement with a third-party investor for the purchase of 1,250,000 shares of common stock at $0.16 per share for $200,000 in cash consideration.

During the month of March 2020, Alpha and Brio exercised their warrants in a cashless exercise for an aggregate of 1,836,155 common stock warrants to obtain 739,291 shares of common stock.

As of June 30, 2020, the Company received $540,972 in cash from investors which is recorded as a liability to issue shares until such time as the shares are issued.

Noncontrolling Interest

For the three months ended June 30, 2020 and 2019, the net loss attributed to the non-controlling interest amounted to $68,131 and $144,887, respectively. During the three months ended June 30, 2020 and 2019, the Company paid distributions to non-controlling shareholders of $85,223 and $0, respectively. For the six months ended June 30, 2020 and 2019, the net loss attributed to the non-controlling interest amounted to $246,947 and $214,742, respectively. During the six months ended June 30, 2020 and 2019, the Company paid distributions to non-controlling shareholders of $121,223 and $34,298, respectively.

On April 25, 2019, the Company entered into an membership purchase agreement with entities owned by the Company’s Chief Executive officer and Chief Technology Officer, Conversion Labs PR, and purchased the remaining 21.8% interest of Conversion Labs PR from the Company’s Chief Executive officer and Chief Technology Officer. As such, the Company now wholly-owns 100% of Conversion labs PR. In order to consummate this transaction, the Company agreed to issue 5 million shares of common stock based on the issuance price of $0.18 per share, equal to $900,000 to the Company’s Chief Executive Officer and Chief Technology Officer. The shares were not issued until August 6, 2019, and, as such, the Company has recorded a liability on the Company’s balance sheet as of June 30, 2019. The difference between the value of the stock issued and net book value of the transfer to accumulated deficit was recognized in non-controlling interest for a charge of $412,377.

Service-Based Stock Options

On January 20, 2020, the Company approved the transition of Mr. Sean Fitzpatrick from the role of the Company’s Chief Acquisition Officer, to the role of President of LegalSimpli. In connection with Mr. Fitzpatrick’s transition, the Company agreed to amend that certain services agreement entered into on July 23, 2018, by and between the Company and Mr. Fitzpatrick, to (i) decrease the number of options to purchase the Company’s common stock previously granted to Mr. Fitzpatrick from 5,000,000 options to 2,500,000 options, 650,000 of which are fully vested as of the effective date and (ii) amend the vesting schedule for the remaining 1,850,000 performance options to include four performance metrics that, if met, each trigger the vesting of 462,500 options. As a result of amendment, the Company cancelled 1,850,000 service based options with an exercise price of $0.30.

During the six months ended June 30, 2020 the Company issued 2.4 million stock options to three employees, two advisory board members, and one vendor of the Company. These stock options have a contractual term of 10 years and vest in 1/3 increments over a two to three year period.

The following is a summary of outstanding service-based options activity for the three months ended June 30, 2020:

	Options Outstanding Number of Shares			Exercise Price per Share		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price per Share
Balance at December 31 2019		15,045,000		$	0.20 - 0.40		4.78 years	$	0.30
Granted		2,400,000			0.23-1.50		7.29 years		0.57
Cancelled		(1,875,000	)	$	0.30		7.50 years		0.30
Expired		–			–		–		–
Balance at June 30, 2020		16,070,000		$	0.16 - 1.50		4.56 years	$	0.34
Exercisable December 31, 2019		11,805,416		$	0.20 - 0.40		3.76 years	$	0.25
Exercisable at June 30, 2020		14,430,416		$	0.20 - 0.40		4.38 years	$	0.26

Performance-Based Stock Options

On January 20, 2020, the Company approved the transition of Mr. Sean Fitzpatrick from the role of the Company’s Chief Acquisition Officer, to the role of President of LegalSimpli. In connection with Mr. Fitzpatrick’s transition, the Company agreed to amend that certain services agreement entered into on July 23, 2018, by and between the Company and Mr. Fitzpatrick, to (i) decrease the number of options to purchase the Company’s common stock previously granted to Mr. Fitzpatrick from 5,000,000 options to 2,500,000 options, 650,000 of which are fully vested as of the effective date and (ii) amend the vesting schedule for the remaining 1,850,000 performance options to include four performance metrics that, if met, each trigger the vesting of 462,500 options. As a result of amendment, the Company cancelled 1,850,000 service based options with an exercise price of $0.30.

The following is a summary of outstanding performance-based options activity for the three months ended June 30, 2020:

	Options Outstanding Number of Shares			Exercise Price per Share		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price per Share
Balance at December 31, 2019		6,825,000		$	0.25 - 0.40		5.59 years	$	0.34
Granted		100,000			1.50		9.25		1.50
Cancelled		(650,000	)		0.30- 0.30		8.06 years		0.30
Expired		–			–		–		–
Balance at June 30, 2020		6,275,000		$	0.25 – 1.50		5.39 years	$	0.36
Exercisable December 31, 2019		3,175,000		$	0.25 - 0.40		2.63 years	$	0.40
Exercisable at June 30, 2020		3,175,000		$	0.25 - 0.40		2.63 years	$	0.40

Warrants

The following is a summary of outstanding and exercisable warrants activity during the three months ended June 30, 2020:

	Warrants Outstanding Number of Shares			Exercise Price per Share		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price per Share
Balance at December 31, 2019		11,326,621		$	0.20 - 0.50		6.02 years	$	0.25
Warrants Granted		5,642,715			0.13 - 0.14		5.49 years		0.12
Warrants Exercised		(9,930,759	)		0.13 - 0.14		1.45 years		0.14
Warrants Expired		-			-		-		-
Balance at June 30, 2020		7,038,181		$	0.13 - 0.50		5.59 years	$	0.31
Exercisable December 31, 2019		10,330,244		$	0.20 - 0.50		6.24 years	$	0.31
Exercisable June 30, 2020		5,745,608		$	0.13 - 0.50		5.62	$	0.34

Alpha Capital Anstalt (“Alpha”) Warrants

On February 25, 2020, the Company and Alpha entered into a Note Repayment and Warrant Amendment Agreement (the “2018 Alpha Amendment”) whereby the Company agreed to (i) repay the outstanding balance of the convertible promissory note issued in favor of Alpha on May 29, 2018 in the amount of $224,145, including principal and interest (the “2018 Alpha Note”) and (ii) amend the exercise price of the warrant (the “2018 Alpha Warrant”) issued to Alpha in connection with the 2018 Alpha Note on May 29, 2018. The 2018 Alpha Warrant originally provided for the purchase of up to 1,956,522 shares of the Company’s common stock at an exercise price of $0.28 per share, none of which have been issued as of the date of the 2018 Alpha Amendment. Pursuant to the terms of the 2018 Alpha Warrant and in connection with the 2018 Alpha Amendment, the Company revised the exercise price of the Alpha 2018 Warrant from $0.28 per share to $0.135 per share and increased the number of shares issuable under the Alpha 2018 Warrant from 1,956,522 to 4,057,972 shares.

On February 25, 2020, the Company and Alpha entered into a Note Repayment and Warrant Amendment Agreement (the “2019 Alpha Amendment”) whereby the Company agreed to (i) repay the outstanding balance of the convertible promissory note issued in favor of Alpha on August 15, 2019 in the amount of $520,000, including principal and interest (the “August 2019 Alpha Note”) and (ii) amend the exercise price of the August 2019 Warrant issued to Alpha in connection with the 2019 Alpha Note on August 15, 2019. The August 2019 Warrant issued to Alpha originally provided for the purchase of up to 1,826,087 shares of the Company’s common stock at an exercise price of $0.28 per share, none of which have been issued as of the date of the 2019 Alpha Amendment. Pursuant to the 2019 Alpha Amendment, Alpha has agreed to the reduction of the exercise price of $0.28 to $0.23. Therefore, effective upon the date of the 2019 Alpha Amendment, the exercise price of the 2019 Alpha Warrant was reduced to $0.23, subject to further adjustment. However, for purposes of calculating additional shares to be issued to Alpha pursuant to the terms of the 2019 Alpha Warrant, the deemed exercise price will be $0.135, as if the exercise price were actually reduced to $0.135 and thereafter increased to $0.23. As a result of the above described reduction of the exercise price and the application of certain provisions of the 2019 Alpha Warrant, the amount of shares that may be purchased upon exercise of the 2019 Alpha Warrant after giving effect to the foregoing is increased to 3,787,439 shares of the Company’s common stock.

As a result of the above transactions, the Company has recorded a deemed distribution to Alpha for the price adjustments of the August 2019 Warrant issued to Alpha of $915,479 which is recorded in the statement of changes in stockholder’s equity as an increase in additional paid in capital and a reduction of accumulated deficit. During the month of March 2020, Alpha exercised a portion of their warrants in a cashless exercise, whereby Alpha exercised 1,336,155 common stock warrants to obtain 451,159 share of common stock.

On May 7, 2020, the Company agreed to further amend August 2019 Warrant issued to Alpha on August 15, 2019, as amended on February 25, 2020 (the “Second Alpha Warrant Amendment”). Specifically, pursuant to anti-dilution provisions contained therein, the Company agreed to amend the August 2019 Warrant issued to Alpha in order to increase the amount of shares able to be purchased thereunder by an additional 1,657,005 shares of the Company’s common stock or an aggregate of up to 5,444,444 shares (the “Alpha Warrant Shares”). On the same day, Alpha exercised, on a cashless basis, all of the August 2019 Warrants issued to Alpha, as amended, resulting in the issuance of 1,957,331 shares of the Company’s common stock to Alpha. Upon Alpha’s cashless exercise, the August 2019 Warrants issued to Alpha are no longer in force or effect and no additional issuances will be due or owing.

Brio Master Fund (“Brio”) Warrants

On February 25, 2020, the Company, and Brio entered into a Warrant Amendment Agreement to amend the exercise price of the warrant issued to Brio on May 29, 2018. The Brio 2018 Warrant originally provided for the purchase of up to 434,783 shares of the Company’s common stock at an exercise price of $0.28 per share, none of which have been issued as of the date of the 2018 Brio Warrant Amendment. Pursuant to the 2018 Brio Warrant Amendment, the Company agreed to revise the exercise price of the 2018 Brio Warrant from $0.28 per share to $0.135 per share and increased the number of shares issuable under the 2018 Brio Warrant from 434,783 to 466,989 shares.

On February 25, 2020, the Company, and Brio entered into a Note Repayment and Warrant Amendment Agreement whereby the Company agreed to (i) repay the outstanding balance of the Convertible Promissory Note issued in favor of Brio on August 15 , 2019 in the amount of $162,500, including principal and interest and (ii) amend the exercise price of the warrant issued to Brio in connection with the 2019 Brio Note on August 15, 2019. The Brio 2019 Warrant originally provide for the purchase of up to 570,652 shares of the Company’s common stock at an exercise price of $0.28 per share, none of which have been issued as of the date of the 2019 Brio Amendment. Pursuant to the 2019 Brio Amendment, Brio has agreed to the reduction of the exercise price of $0.28 to $0.23. Therefore, effective upon the date of the 2019 Brio Amendment, the exercise price of the 2019 Brio Warrant is reduced to $0.23, subject to further adjustment. However, for purposes of calculating additional shares to be issued to Brio pursuant to the terms of the 2019 Brio Warrant, the deemed exercise price will be $0.135, as if the exercise price were actually reduced to $0.135 and thereafter increased to $0.23. As a result of the above described reduction of the exercise price and the application of certain provisions of the 2019 Brio Warrant, the amount of shares that may be purchased upon exercise of the 2019 Brio Warrant after giving effect to the foregoing is increased to 1,183,575 shares of the Company’s common stock.

As a result of the above transactions, the Company has recorded a deemed distribution to Alpha for the price adjustments of the Alpha warrants of $226,906 which is recorded in the statement of changes in stockholder’s equity as an increase in additional paid in capital and a reduction of accumulated deficit. During the month of March 2020, Brio exercised a portion of their warrants in a cashless exercise, whereby Alpha exercised 500,000 common stock warrants to obtain 287,736 shares of common stock.

On May 7, 2020, the Company agreed to further amend those certain warrants issued to Brio on August 15, 2019, as amended on February 25, 2020. Specifically, pursuant to anti-dilution provisions therein, the Company agreed to amend the 2019 Brio Warrant in order to increase the amount of shares able to be purchased thereunder by an additional 517,814 shares of the Company’s common stock or an aggregate of up to 1,701,389. On the same day, Brio exercised on a cashless basis the Brio Warrants in full resulting in the issuance of 611,666 shares of the Company’s common stock to Brio. Upon Brio’s cashless exercise, the 2019 Brio Warrants are no longer in force or effect and no additional issuances will be due or owing.

Stock-based Compensation

The total stock-based compensation expense related to Service-Based Stock Options, Performance-Based Stock Options and Warrants issued for service amounted to approximately $439,000 and $191,000 for the three months ended June 30, 2020 and 2019, respectively. The total stock-based compensation expense related to Service-Based Stock Options, Performance-Based Stock Options and Warrants issued for service amounted to $535,000 and $373,000 for the six months ended June 30, 2020 and 2019, respectively. Such amounts are included in general and administrative expenses in the consolidated statement of operations.

XML

Leases

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Leases

NOTE 6– LEASES

The Company primarily leases office space and other equipment using month to month terms. Conversion Labs PR utilizes office space in Puerto Rico which is subleased from Mr. Schreiber (the Company’s President and CEO) on a month to month basis and incurs expense of approximately $4,000 a month for this office space.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes all existing guidance on accounting for leases in ASC Topic 840. ASU 2016-02 is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. ASU 2016-02 will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We have reviewed ASC 842 and have determined the following impact on our financial statements:

	2020
Right of Use Asset		19,990
Lease liability		28,917

In February 2018, the Company entered into a 3-year agreement to lease office space in Huntington Beach, California beginning on March 2, 2018. The rent is payable on a monthly basis in the amount of $2,106 for the first twelve months, $2,149 for the second twelve months and $2,235 for the third twelve months. A security deposit of $2,235 was paid for this lease. The Company has classified this as an operating lease and have recorded the straight-line lease expense in the accompanying statement of operations.

XML

Commitments and Contingencies

6 Months Ended

Jun. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 7 - COMMITMENTS AND CONTINGENCIES

Royalty Agreements

During 2016, Conversion Labs PR entered into a sole and exclusive license, royalty and advisory agreement with Pilaris Laboratories, LLC (“Pilaris”) relating to Pilaris’ PilarisMax shampoo formulation and conditioner. The term of the agreement will be the life of the US Patent held by Pilaris. As consideration for granting Conversion Labs PR this license, Pilaris will receive on quarterly basis, 10% of the net income collected by the licensed products based on the following formula: Net Income = total income – cost of goods sold – advertising and operating expenses directly related to the marketing of the licensed products. In addition, Conversion Labs PR shall pay Pilaris a performance fee of $50,000 on the 180-day anniversary of the agreement and an additional $50,000 performance fee on the 365-day anniversary of the agreement. For the year ended December 31, 2018, the Company capitalized the license fee in the amount of $100,000, as the purchase of the fee is deemed an asset purchase under ASC 805. In April 2017, the Company issued 217,390 shares of common stock and 108,696 warrants, pursuant to a subscription agreement, for the stated consideration and satisfaction of obligation to pay $50,000 on the 180-day anniversary of the execution of this agreement. As of June 30, 2020 and December 31, 2019, the $0 and $0, respectively was included in accounts payable and accrued expenses in regard to this agreement.

During 2018, the Company entered into a license agreement (the “Alphabet Agreement”) with M.ALPHABET, LLC (“Alphabet”), pursuant to which Alphabet agreed to license its PURPUREX business which consists of methods and compositions developed by Alphabet for the treatment of purpura, bruising, post-procedural bruising and traumatic bruising (the “Product Line”). Pursuant to the license granted under the Alphabet Agreement, Conversion Labs PR obtains an exclusive license to incorporate (i) any intellectual property rights related to the Product Line and (ii) all designs, drawings, formulas, chemical compositions and specifications used or useable in the Product Line into one or more products manufactured, sold, and/or distributed by Alphabet for the treatment of purpura, bruising, post-procedural bruising and traumatic bruising and for all other fields of use or purposes (the “Licensed Product(s)”), and to make, have made, advertise, promote, market, sell, import, export, use, offer to sell and distribute the Licensed Product(s) throughout the world with the exception of China, Hong Kong, Japan, and Australia (the “License”).

The Company shall pay Alphabet a royalty equal to 13% of Gross Receipts (as defined in the Agreement) realized from the sales of Licensed Products. Further, so long as the Agreement is not previously terminated, the Company, also agreed to pay Alphabet $50,000 on the 120-day anniversary of the Agreement and an additional $50,000 on the 360-day anniversary of the Agreement.

Upon execution of the Alphabet Agreement, Alphabet was granted a 10-year option to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.50. Further, if Licensed Products have gross receipts of $7,500,000 in any calendar year, the Company will grant Alphabet an option to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.50; (ii) if Licensed Products have gross receipts of $10,000,000 in any calendar year, the Company will grant Alphabet an additional option to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.50 and (iii) If Licensed Products have gross receipts of $20,000,000 in any calendar year, the Company will grant Alphabet an option to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.75.

Employment and Consulting Agreements

The Company has entered into various agreements with officers, directors, employees and consultants that expire in one to five years.

Legal Matters

In the normal course of business operations, the Company may become involved in various legal matters. As of June 30, 2020, the Company’s management does not believe that there are any potential legal matters that could have an adverse effect on the Company’s financial position.

XML

Related Party Transactions

6 Months Ended

Jun. 30, 2020

Related Party Transactions [Abstract]

Related Party Transactions

NOTE 8 – RELATED PARTY TRANSACTIONS

Chief Executive Officer

Conversion Labs PR utilizes office space in Puerto Rico which is subleased from Mr. Schreiber (President and CEO) incurs expense of approximately $4,000 to $5,000 a month for this office space for which the Company and the CEO do not have a written lease agreement. Payments to JLS Ventures, an entity wholly owned by our Chief Executive Officer, Mr. Schreiber, for rent on Conversion Labs PR’s Puerto Rico office space amounted to $15,000 and $12,000 for the three months ended June 30, 2020 and 2019, respectively.

Conversion Labs PR utilizes BV Global Fulfillment, owned by a related person of the Company’s current Chief Executive Officer to warehouse a majority of the Company’s finished goods inventory and for fulfillment services. The Company pays a monthly fee of $13,000 to $16,000 for fulfillment services and reimburses BV Global Fulfillment for their direct costs associated with shipping the Company’s products. As of June 30, 2020 and December 31, 2019, the Company owed BV Global Fulfillment $161,823 and $53,026, respectively, which are included in accounts payable and accrued liabilities on the accompany consolidated balance sheets.

XML

Subsequent Events

6 Months Ended

Jun. 30, 2020

Subsequent Events [Abstract]

Subsequent Events

NOTE 9 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date these financial statements were issued and has identified the following:

On July 27, 2020, the Company issued a secured convertible promissory Note in the principal amount of up to $1,500,000, to an accredited investor. The Company received $600,000 in aggregate gross proceeds. Any additional advances under this note would require the approval of the lender in its sole discretion. This note accrues interest at a rate of one and one-quarter percent (1.25%) per month and matures on January 24, 2021. Upon the closing of a Qualified Financing prior to repayment of this note, upon the written election by the investor, the outstanding principal and all accrued but unpaid interest thereon shall convert into fully paid and nonassessable shares of the preferred stock, par value $0.001 per share, of the Company issued and sold by the Company at the closing of a Qualified Financing. Upon such written election by the lender, this note shall convert into the number of shares of preferred stock (including fractional shares) equal to the quotient of (i) the outstanding principal and accrued but unpaid interest on this note, divided by (ii) the price per share paid by the cash purchasers of the preferred stock sold in such Qualified Financing. “Qualified Financing” means a transaction or series of transactions with the principal purpose of raising capital pursuant to which the Company issues and sells shares of preferred stock for aggregate gross proceeds of at least $2,500,000 (excluding all proceeds from the incurrence of indebtedness, including this note, that is converted into such preferred stock, or otherwise cancelled in consideration for the issuance of such preferred stock). As collateral security for the Company’s obligations under this note, the Company pledged, assigned and transferred to the investor a first priority security interest in and collateral assignment of the Company’s right, title and interest in and to all of the Company’s tangible and intangible property. This note contains customary events of default (each an “Event of Default”). If an Event of Default occurs, all outstanding obligations owing under this note will become immediately due and payable at the investor’s election.

During August 2020, the Company offered an inducement to all warrant holders of our $0.40 warrants for a total 2,634,228 common stock warrants outstanding by offering a $0.05 discount on the exercise price of these warrants if they immediately exercised. The adjusted exercise price of these warrants would become $0.35. To date, a vast majority of our warrant holders have exercised this discount, but the Company is still in the process of completing the inducement.

XML

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”).

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Conversion Labs PR and its majority owned subsidiary, LegalSimpli. The non-controlling interest in LegalSimpli represents the 49% equity interest held by other members of the subsidiary. All significant consolidated transactions and balances have been eliminated in consolidation.

Use of Estimates

Use of Estimates

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the determination of reserves (if necessary) for accounts receivable, returns and allowances, useful life of intangible and right of use assets, the valuation of inventory and inputs into the provision for lease liabilities and stockholders’ equity-based transactions. Actual results could differ from those estimates.

Reclassifications

Reclassifications

Certain reclassifications have been made to conform the prior year’s data to the current presentation. These reclassifications have no effect on previously reported operations, stockholders’ equity (deficit) or cash flows. Given the increase in the Company’s software business and to conform the Company’s presentation of operating results to industry standards, the Company has changed their categories for reporting operations, as result the Company has made reclassifications to the prior year presentation in order to conform it to the current presentation.

Revenue Recognition

Revenue Recognition

The Company records revenue under the adoption of ASC 606 by analyzing exchanges with its customers using a five-step analysis:

1.	Identify the contract
2.	Identify performance obligations
3.	Determine the transaction price
4.	Allocate the transaction price
5.	Recognize revenue

For the Company’s product-based contracts with customers, the Company has determined that there is one performance obligation and the delivery of this performance obligation is transferred at a point in time. The Company generally records sales of finished products once the customer places and pays for the order and the product is simultaneously shipped by a third-party fulfillment service provider, but in limited cases if title does not pass until the product reaches the customer’s delivery site, then recognition of revenue should be deferred until that time, however the Company does not have a process to properly record the recognition of revenue if orders are not immediately shipped. Delivery is considered to have occurred when title and risk of loss have transferred to the customer, which is usually upon shipment of the product. The Company does sell a subscription based service which is based on the recurring shipment of products and billed as if the Company were receiving recurring revenues and orders each month, therefore, the Company records these upon each shipment to the customer.

The Company records an estimate for provisions of discounts, returns, allowances, customer rebates and other adjustments for each shipment, and are netted with gross sales. The Company’s discounts and customer rebates are known at the time of sale and the Company appropriately debits net product revenues for these transactions based on the known discount and customer rebates. The Company estimates for customer returns and allowances based on estimates of historical transactions and accounts for such provisions during the same period in which the related revenues are earned. The Company has determined that the population of contracts with customers tends to be homogenous, so that review of the contracts and estimate of various revenue related adjustments can be applied to the entire portfolio population. Customer discounts, returns and rebates on product revenues during the three months ended June 30, 2020 and 2019 approximated $857,000 and $161,000, respectively. Customer discounts, returns and rebates on product revenues during the six months ended June 30, 2020 and 2019 approximated $1,334,000 and $713,000, respectively. 

The Company began testing trial offers with the Shapiro MD products in late 2018. The Company was unable to adequately implement a process to report any trial-based sales and the related impact on inventory. Given the relatively new trail period being offered, the Company has not been able to estimate the historical effect to determine how this will change the recording of revenue or expected reserve for return rates.

The Company, through its majority-owned subsidiary LegalSimpli, offers a suite of software to customers as a monthly subscription based service. This suite of software allows the user or subscriber to convert almost any type of document to other editable document type formats for easy editing. For these subscription-based contracts with customers, the Company offers a 14-day trial period which is billed at $1.95 for an initial period, a monthly subscription, or a yearly subscription to the Company’s software. The Company has estimated that there is one product and performance obligation that is delivered over time, as the Company allows the subscriber to access the service for the time period purchased. The Company allows the customer to cancel at any point during the billing cycle, in which case the customers subscription will not be renewed for the following month or year depending on the original subscription. The Company records the sales over the customers subscription period for monthly and yearly subscribers or at the end of the initial 14 day service period for customers who purchased the initial subscription. The Company offers a discount for the purchase of the monthly and yearly subscriptions, which must be paid at the initiation of the contract term, so that the Contract price is fixed at the contract initiation. Yearly and monthly subscriptions for the subscription are recorded net of the Company’s known discount rates. As of June 30, 2020 and December 31, 2019, the Company has accrued contract liabilities of approximately $304,000 and $110,000, respectively, which represent obligations on in-process monthly or yearly contracts with customers and yet to be recognized initial 14-day trial periods.

For the six months ended June 30, 2020 and 2019, the Company had the following disaggregated revenue :

	Six Months Ended June 30,
	2020		%			2019		%
Product revenues by Brand for Conversion Labs PR:
Shapiro MD	$	8,156,378		61	%	$	4,413,157		82	%
Rex MD		2,515,560		19	%		-		-
iNR Wellness		119,254		1	%		233,594		4	%
Purpurex		30,317		0	%		10,232		0	%
Scarology		4,105		0	%		18,726		0	%
Innate		0		0	%		4,081		0	%
Total product revenue for Conversion Labs PR	$	10,825,614		81	%	$	4,679,790		86	%
Software revenue for LegalSimpli		2,568,981		19	%		717,607		14	%
Total net revenue	$	13,394,595		100	%	$	5,397,397		100	%

Accounts Receivable

Accounts Receivable

Accounts receivable are carried at original sales amount less an estimate made for returns, chargebacks, and discounts. Accounts receivables mainly consist of receivables from third-party merchant processors which are settled with a couple of days. Management determines the need, if any, for an allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers’ accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. As of June 30, 2020 and 2019, the Company had determined that an allowance for doubtful accounts reserve was not necessary. As of June 30, 2020 and December 31, 2019, the reserve for sales returns and allowances was approximately $351,000 and $82,000, respectively.

Inventory

Inventory

As of June 30, 2020 and December 31, 2019, inventory consisted primarily of finished cosmetic products. Inventory is maintained at the Company’s third-party warehouse location, which is owned by a related party, in Pennsylvania and at Amazon fulfillment centers.

Inventory is valued at the lower of cost or net realizable value with cost determined on a first-in, first-out (“FIFO”) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to net realizable, if lower. As of June 30, 2020 and December 31, 2019, the Company recorded an inventory reserve in the amount of $34,657 and $12,500, respectively. The increase in our inventory reserve mainly is attributable to the lack of marketability for our INR Wellness product line. As of June 30, 2020 and December 31, 2019, the Company’s inventory consisted of the following:

	June 30, 2020		December 31, 2019
Raw materials and packaging components	$	291,033	$	37,542
Finished products		517,813		912,517
Total net inventory	$	808,846	$	950,059

Product Deposit

Product Deposit

Many of our vendors require deposits when a purchase order is placed for goods or fulfillment services. These deposits typically ranging from 10% to 33% of the total purchased amount. Our vendors issue a credit memo when sending their final invoice, reducing the amount the Company owes for the deposit amount previously paid to the vendors. The Company capitalizes these product deposits until the inventory is received at the Company’s fulfillment centers. As of June 30, 2020 and December 31, 2019, the Company has approximately $281,000 and $150,000, respectively, of product deposits with multiple vendors for the purchase of raw materials or finished for products we sell online. As of June 30, 2020 and December 31, 2019, the vast majority of these product deposits are with one vendor that manufacturers the Company’s finished goods inventory for its Shapiro hair care product line. 

Capitalized Software Costs

Capitalized Software Costs

The Company capitalizes certain payroll and third-party costs related to internally developed software and amortize these costs using the straight-line method over the estimated useful life of the software, generally two years. The Company does not sell internally developed software other than through the use of subscription service. Certain development costs not meeting the criteria for capitalization, in accordance with Accounting Standards Codification (“ASC”) ASC 350-40 Internal-Use Software, are expensed as incurred. As of June 30, 2020 and 2019, the Company capitalized $317,160 and $0 related to internally developed software costs which is included in development. As of June 30, 2020, these costs include $40,000 in capitalized stock based compensation that was given to a third-party service provider. During the three months ending June 30, 2020 and 2019, the Company amortized $11,585 and $0 of capitalized software costs, respectively.

Intangible Assets

Intangible Assets

Intangible assets are comprised of customer relationship asset and purchased licenses with estimated useful lives of three years and indefinite lived, respectively. Intangible assets are amortized over their estimated lives using the straight-line method. Costs incurred to renew or extend the term of recognized intangible assets are capitalized and amortized over the useful life of the asset. 

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Long-lived assets are evaluated for impairment whenever events or changes in circumstances have indicated that an asset may not be recoverable and are grouped with other assets to the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities (asset group). If the sum of the projected undiscounted cash flows (excluding interest charges) of an asset group is less than its carrying value and the fair value of an asset group is also less than its carrying value, the assets will be written down by the amount by which the carrying value of the asset group exceeded its fair value. However, the carrying amount of a finite-lived intangible asset can never be written down below its fair value. Any loss would be recognized in income from continuing operations in the period in which the determination is made.

Liability to Issue Common Stock

Liability to Issue Common Stock

Liability to issue common stock represents liabilities of the Company for failing to issue shares of common stock timely to various consultants and or third-party investors in conjunction with various consulting, service, warrant or stock purchase agreements. As of June 30, 2020, the Company has a liability to issue 2,627,635 shares of common stock for $541,972 in fair value. During the six months ended June 30, 3020, the Company received $1,639,000 in cash from investors which was recorded as a liability to issue shares until such time as the shares were issued. The yet to be issued shares of common stock are valued based on the fair market value of the common stock price on the date of agreement or the purchase price specified in the stock purchase agreement.

Income Taxes

Income Taxes

The Company files corporate federal and state tax returns. Conversion Labs PR and LegalSimpli file tax returns in Puerto Rico, both are limited liability companies and file separate tax returns with any tax liabilities or benefits passing through to its members.

The Company records current and deferred taxes in accordance with Accounting Standards Codification (“ASC”) 740, “Accounting for Income Taxes.” This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company’s tax returns for all years since December 31, 2016, remain open to taxing authorities.

Stock-Based Compensation

Stock-Based Compensation

The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting or service period. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company’s common stock shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.

Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

Earnings (Loss) Per Share

Earnings (Loss) Per Share

Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.

Common stock equivalents comprising shares underlying 17,498,953 options and warrants for the three and six months ended June 30, 2020 have not been included in the loss per share calculations as the effects are anti-dilutive.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The carrying value of the Company’s financial instruments, including cash, accounts receivable, accounts payable and accrued expenses and the face amount of notes payable approximate fair value for all periods.

Concentrations of Risk

Concentrations of Risk

The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.

The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.

We are dependent on certain third-party manufacturers, although we believe that other contract manufacturers could be quickly secured if any of our current manufacturers cease to perform adequately. As of June 30, 2020 and December 31, 2019, we utilized two (2) suppliers for fulfillment services, two (2) suppliers for manufacturing finished goods, one (1) supplier for packaging and bottles and one (1) supplier for labeling. For the three and six months ended June 30, 2020 and the year ended December 31, 2019, we purchased 100% of our finished goods from two (2) manufacturers.

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. We do not expect the implementation of this new pronouncement to have a material impact on our consolidated financial statements.

In July 2017, the FASB issued ASU No. 2017-11, “Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features” (“ASU 2017-11”). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share (“EPS”) reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard was adopted on January 1, 2020 and did not have a material impact on the Company’s financial position, results of operations or cash flows.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

All other accounting standards updates that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

XML

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Schedule of Disaggregated Revenue

For the six months ended June 30, 2020 and 2019, the Company had the following disaggregated revenue :

	Six Months Ended June 30,
	2020		%			2019		%
Product revenues by Brand for Conversion Labs PR:
Shapiro MD	$	8,156,378		61	%	$	4,413,157		82	%
Rex MD		2,515,560		19	%		-		-
iNR Wellness		119,254		1	%		233,594		4	%
Purpurex		30,317		0	%		10,232		0	%
Scarology		4,105		0	%		18,726		0	%
Innate		0		0	%		4,081		0	%
Total product revenue for Conversion Labs PR	$	10,825,614		81	%	$	4,679,790		86	%
Software revenue for LegalSimpli		2,568,981		19	%		717,607		14	%
Total net revenue	$	13,394,595		100	%	$	5,397,397		100	%

Summary of Inventory

As of June 30, 2020 and December 31, 2019, the Company’s inventory consisted of the following:

	June 30, 2020		December 31, 2019
Raw materials and packaging components	$	291,033	$	37,542
Finished products		517,813		912,517
Total net inventory	$	808,846	$	950,059

XML

Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

As of June 30, 2020, the Company has the following amounts related to intangible assets:

	Gross Carrying Amount		Accumulated Amortization
Amortizable intangible assets
Customer relationship asset	$	1,006,840	$	(699,194	)
Indefinite lived intangible assets
Purchased licenses		200,000		-
	$	1,206,840	$	(699,194	)

As of December 31, 2019 the Company has the following amounts related to intangible assets:

	Gross Carrying Amount		Accumulated Amortization
Amortizable intangible assets:
Customer relationship asset	$	1,006,840	$	(531,388	)
Indefinite lived intangible assets:
Purchased licenses		200,000		-
	$	1,206,840	$	(531,388	)

XML

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2020

Schedule of Warrant Outstanding and Exercisable

The following is a summary of outstanding and exercisable warrants activity during the three months ended June 30, 2020:

	Warrants Outstanding Number of Shares			Exercise Price per Share		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price per Share
Balance at December 31, 2019		11,326,621		$	0.20 - 0.50		6.02 years	$	0.25
Warrants Granted		5,642,715			0.13 - 0.14		5.49 years		0.12
Warrants Exercised		(9,930,759	)		0.13 - 0.14		1.45 years		0.14
Warrants Expired		-			-		-		-
Balance at June 30, 2020		7,038,181		$	0.13 - 0.50		5.59 years	$	0.31
Exercisable December 31, 2019		10,330,244		$	0.20 - 0.50		6.24 years	$	0.31
Exercisable June 30, 2020		5,745,608		$	0.13 - 0.50		5.62	$	0.34

Service-Based Stock Options [Member]

Schedule of Option Activity

The following is a summary of outstanding service-based options activity for the three months ended June 30, 2020:

	Options Outstanding Number of Shares			Exercise Price per Share		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price per Share
Balance at December 31 2019		15,045,000		$	0.20 - 0.40		4.78 years	$	0.30
Granted		2,400,000			0.23-1.50		7.29 years		0.57
Cancelled		(1,875,000	)	$	0.30		7.50 years		0.30
Expired		–			–		–		–
Balance at June 30, 2020		16,070,000		$	0.16 - 1.50		4.56 years	$	0.34
Exercisable December 31, 2019		11,805,416		$	0.20 - 0.40		3.76 years	$	0.25
Exercisable at June 30, 2020		14,430,416		$	0.20 - 0.40		4.38 years	$	0.26

Performance-Based Stock Options [Member]

Schedule of Option Activity

The following is a summary of outstanding performance-based options activity for the three months ended June 30, 2020:

	Options Outstanding Number of Shares			Exercise Price per Share		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price per Share
Balance at December 31, 2019		6,825,000		$	0.25 - 0.40		5.59 years	$	0.34
Granted		100,000			1.50		9.25		1.50
Cancelled		(650,000	)		0.30- 0.30		8.06 years		0.30
Expired		–			–		–		–
Balance at June 30, 2020		6,275,000		$	0.25 – 1.50		5.39 years	$	0.36
Exercisable December 31, 2019		3,175,000		$	0.25 - 0.40		2.63 years	$	0.40
Exercisable at June 30, 2020		3,175,000		$	0.25 - 0.40		2.63 years	$	0.40

XML

Leases (Tables)

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Schedule of Leases

We have reviewed ASC 842 and have determined the following impact on our financial statements:

	2020
Right of Use Asset		19,990
Lease liability		28,917

XML

Nature of the Organization and Business (Details Narrative) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2018	Apr. 01, 2016
Accumulated deficit	$ (23,705,170)	$ (16,594,917)
Through the Next 12 Months [Member]
Additional cash	$ 4,000,000
Immudyne PR LLC [Member]
Percentage of ownership equity interest				78.20%
LegalSimpli Software, LLC [Member]
Percentage of purchase business acquired			51.00%

XML

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Subscription price per share	$ 1.95		$ 1.95
Accrued contract liabilities	$ 303,670		$ 303,670		$ 109,552
Accounts receivable reserve	351,000		351,000		82,000
Inventory reserve	34,657		34,657		12,500
Product deposit	281,143		281,143		$ 150,000
Capitalized software costs	317,160	$ 0	317,160	$ 0
Amortization of capitalized software			$ 11,585
Liability to issuance of common stock			2,627,635
Common stock fair value	541,972		$ 541,972
Cash receipts from investors for unissued shares			$ 1,639,000
Two Manufacturers [Member]
Concentration risk, percentage			100.00%		100.00%
Options and Warrants [Member]
Antidilutive securities excluded from computation of earnings per share			17,498,953
Capitalized Stock-Based Compensation [Member]
Capitalized software costs	40,000		$ 40,000
Minimum [Member]
Deposits percentage			10.00%
Maximum [Member]
Deposits percentage			33.00%
Product Revenues, Net [Member]
Customer discounts, returns and rebates	$ 857,000	$ 161,000	$ 1,334,000	$ 713,000
LegalSimpli Software, LLC [Member]
Non-controlling interest rate			49.00%

XML

Summary of Significant Accounting Policies - Schedule of Disaggregated Revenue (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Product Revenues, Net [Member] | CVLB PR [Member]
Total net revenue	$ 10,825,614	$ 4,679,790
Net revenue, percentage	81.00%	86.00%
Product Revenues, Net [Member] | Shapiro MD [Member] | CVLB PR [Member]
Total net revenue	$ 8,156,378	$ 4,413,157
Net revenue, percentage	61.00%	82.00%
Product Revenues, Net [Member] | Rex MD [Member] | CVLB PR [Member]
Total net revenue	$ 2,515,560
Net revenue, percentage	19.00%
Product Revenues, Net [Member] | iNR Wellness [Member] | CVLB PR [Member]
Total net revenue	$ 119,254	$ 233,594
Net revenue, percentage	1.00%	4.00%
Product Revenues, Net [Member] | Purpurex [Member] | CVLB PR [Member]
Total net revenue	$ 30,317	$ 10,232
Net revenue, percentage	0.00%	0.00%
Product Revenues, Net [Member] | Scarology [Member] | CVLB PR [Member]
Total net revenue	$ 4,105	$ 18,726
Net revenue, percentage	0.00%	0.00%
Product Revenues, Net [Member] | Innate [Member] | CVLB PR [Member]
Total net revenue	$ 0	$ 4,081
Net revenue, percentage	0.00%	0.00%
Software Revenues, Net [Member] | LegalSimpli Software, LLC [Member]
Total net revenue	$ 2,568,981	$ 717,607
Net revenue, percentage	19.00%	14.00%
Service Revenues, Net [Member] | Conversion Labs Media, LLC [Member]
Total net revenue	$ 13,394,595	$ 5,397,397
Net revenue, percentage	100.00%	100.00%

XML

Summary of Significant Accounting Policies - Summary of Inventory (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Raw materials and packaging components	$ 291,033	$ 37,542
Finished products	517,813	912,517
Total net inventory	$ 808,846	$ 950,059

XML

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 83,903	$ 83,903	$ 167,806	$ 167,807
Amortization expense 2020	336,000		336,000
Amortization expense 2021	$ 140,000		$ 140,000

XML

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Gross Carrying Amount	$ 1,206,840	$ 1,206,840
Accumulated Amortization	(699,194)	(531,388)
Customer Relationship Asset [Member]
Gross Carrying Amount	1,006,840	1,006,840
Accumulated Amortization	(699,194)	(531,388)
Purchased Licenses [Member]
Gross Carrying Amount	200,000	200,000
Accumulated Amortization

XML

Notes Payable - (Details Narrative) - USD ($)					3 Months Ended		6 Months Ended		12 Months Ended
	May 27, 2020	Feb. 18, 2020	Aug. 15, 2019	May 29, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2020	Feb. 25, 2020	Feb. 15, 2020
Repayments of notes payable							$ 2,498,808	$ 70,870
Proceeds from note payable							1,750,000	50,000
Convertible Note Payable [Member]
Interest expense on notes payable					$ 228,875	$ 129,826	1,021,914	300,000
6 Accredited Investors [Member] | May 2020 Notes [Member]
Debt instrument, interest rate	12.00%
Debt, voluntary conversion price per share	$ 0.50
Aggregate principal amount	$ 1,000,000
Proceeds from convertible promissory notes	$ 1,000,000
Restricted common stock	665,000
Increase outstanding notes percentage	130.00%
Securities Purchase Agreement [Member] | Three Accredited Investors [Member]
Debt instrument, face amount			$ 1,291,500
Debt instrument, interest rate			12.00%
Debt instrument, conversion rate			4.99%
Debt, voluntary conversion price per share			$ 0.23
Debt interest, maturity date			Aug. 15, 2020
Original issue discount, percentage			20.00%
Original issue discount, value			$ 215,250
Proceeds from note payable			1,291,500
Debt issuance costs			$ 284,070
Securities Purchase Agreement [Member] | Three Accredited Investors [Member] | In Conjuction with Convertible Notes Payable [Member]
Warrants exercise price per share			$ 0.28
Value of warrants			569,147
Securities Purchase Agreement [Member] | Three Accredited Investors [Member] | Maximum [Member]
Number of warrants to purchase common stock			4,679,348
Securities Purchase Agreement [Member] | Alpha Capital Anstalt and Brio Capital Master Fund Ltd. [Member]
Debt instrument, face amount				$ 550,000
Number of warrants to purchase common stock				2,391,305
Debt instrument, interest rate				12.00%
Debt instrument, conversion rate				4.99%
Debt, voluntary conversion price per share				$ 0.23
Debt conversion, converted value									$ 344,642	$ 344,642
Debt conversion, interest value									9,922	$ 9,922
Debt interest, maturity date				May 31, 2019
Note Repayment and Warrant Amendment Agreement [Member] | Alpha Capital Anstalt and Brio Capital Master Fund Ltd. [Member]
Debt instrument, face amount												$ 1,291,000
Original issue discount, value					568,322		568,322		404,393
Debt issuance costs												$ 500,145
Note payable					0		0		1,291,000
Notes payable, current					0		0		$ 627,426
C6 Purchase Agreements [Member] | C6 Capital, LLC [Member]
Debt instrument, face amount		$ 1,020,000
Repayments of notes payable		$ 750,000
Original issue discount, percentage		18.00%
Original issue discount, value		$ 270,000
Debt issuance costs		15,000
C6 Purchase Agreements [Member] | C6 Capital, LLC [Member] | Daily Average Payment [Member]
Repayments of notes payable		8,094
C6 Purchase Agreements [Member] | C6 Capital, LLC [Member] | Per Agreement [Member]
Original issue discount, value		135,000
C6 Purchase Agreement One [Member] | C6 Capital, LLC [Member]
Repayments of notes payable		375,000
C6 Purchase Agreement Two [Member] | C6 Capital, LLC [Member]
Repayments of notes payable		375,000
C6 Purchase Agreements One [Member] | C6 Capital, LLC [Member]
Debt issuance costs		7,500
C6 Purchase Agreements Two [Member] | C6 Capital, LLC [Member]
Debt issuance costs		$ 7,500
Two C6 Purchase Agreements [Member] | C6 Capital, LLC [Member]
Debt instrument, face amount					161,904		161,904
Original issue discount, value					600,424		600,424
Note payable					$ 858,000		$ 858,000
Debt instrument, unamortized discount, net											$ 27,329
Paycheck Protection Program Loan [Member] | US Small Business Administration [Member]
Debt instrument, face amount						$ 242,000		$ 242,000
Debt instrument, interest rate						1.00%		1.00%					60.00%
Non-payroll expenses percentage													40.00%

XML

Stockholder's Equity (Details Narrative) - USD ($)					1 Months Ended	3 Months Ended				6 Months Ended
	May 07, 2020	Feb. 25, 2020	Jan. 20, 2020	Apr. 25, 2019	Feb. 29, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Cash consideration						$ 250,000
Cash receipts from investors for unissued shares										$ 1,639,000
Net loss attributed to non-controlling interest						(68,131)		$ (144,887)		(206,947)	(214,702)
Distributions to non-controlling interest						72,000		72,000		(121,223)	(34,298)
Accumulated deficit						(23,705,170)				(23,705,170)		$ (16,594,917)
Deemed distribution from warrant price adjustments
Value of shares issued for compensation						$ 438,575	$ 95,900	$ 218,460	$ 154,600	$ 535,000	$ 373,000
Brio Capital Master Fund Ltd. [Member] | 2019 Brio Warrant [Member]
Issuance of common stock, shares	611,666
Additional shares of common stock	517,814
Maximum [Member] | Brio Capital Master Fund Ltd. [Member] | 2019 Brio Warrant [Member]
Issuance of common stock, shares	1,701,389
Service-Based Stock Options [Member]
Number of shares cancelled during period										1,875,000
Stock options issued						16,070,000				16,070,000		15,045,000
Note Repayment and Warrant Amendment Agreement [Member] | Alpha Capital Anstalt [Member]
Issuance of common stock, shares		451,159
Cashless exercise of warrants, shares		1,336,155
Deemed distribution from warrant price adjustments		$ 915,479
Note Repayment and Warrant Amendment Agreement [Member] | Alpha Capital Anstalt [Member] | 2018 Alpha Note [Member]
Convertible promissory note		$ 224,145
Warrant exercise price		$ 0.28
Note Repayment and Warrant Amendment Agreement [Member] | Alpha Capital Anstalt [Member] | 2019 Alpha Note [Member]
Options to purchase shares of common stock		1,826,087
Convertible promissory note		$ 520,000
Warrant exercise price		$ 0.28
Warrant exercise price description		The exercise price were actually reduced to $0.135 and thereafter increased to $0.23.
Note Repayment and Warrant Amendment Agreement [Member] | Brio Master Fund [Member]
Issuance of common stock, shares		287,736
Cashless exercise of warrants, shares		500,000
Deemed distribution from warrant price adjustments		$ 226,906
Note Repayment and Warrant Amendment Agreement [Member] | Brio Master Fund [Member] | Brio 2019 Warrant [Member]
Convertible promissory note		$ 162,500
Warrant exercise price		$ 0.28
Warrant exercise price description		Effective upon the date of the 2019 Brio Amendment, the exercise price of the 2019 Brio Warrant is reduced to $0.23, subject to further adjustment.
Note Repayment and Warrant Amendment Agreement [Member] | Maximum [Member] | Alpha Capital Anstalt [Member] | 2018 Alpha Note [Member]
Options to purchase shares of common stock		1,956,522
Note Repayment and Warrant Amendment Agreement [Member] | Maximum [Member] | Brio Master Fund [Member] | Brio 2018 Warrant [Member]
Options to purchase shares of common stock		434,783
Warrant exercise price		$ 0.28
Note Repayment and Warrant Amendment Agreement [Member] | Maximum [Member] | Brio Master Fund [Member] | Brio 2019 Warrant [Member]
Options to purchase shares of common stock		570,652
2018 Alpha Amendment [Member] | Maximum [Member] | Alpha Capital Anstalt [Member] | 2018 Alpha Warrant [Member]
Warrant exercise price		$ 0.135
Warrant		4,057,972
2018 Alpha Amendment [Member] | Minimum [Member] | Alpha Capital Anstalt [Member] | 2018 Alpha Warrant [Member]
Warrant exercise price		$ 0.28
Warrant		1,956,522
2019 Alpha Amendment [Member] | Alpha Capital Anstalt [Member] | 2019 Alpha Warrant [Member]
Deemed warrant exercise price		$ 0.135
2019 Alpha Amendment [Member] | Maximum [Member] | Alpha Capital Anstalt [Member] | 2019 Alpha Warrant [Member]
Warrant exercise price		$ 0.23
Warrant to purchase of common stock		3,787,439
2019 Alpha Amendment [Member] | Minimum [Member] | Alpha Capital Anstalt [Member] | 2019 Alpha Warrant [Member]
Warrant exercise price		$ 0.28
Second Alpha Warrant Amendment [Member] | August 2019 Warrant [Member]
Issuance of common stock, shares	1,957,331
Additional shares of common stock	1,657,005
Second Alpha Warrant Amendment [Member] | Maximum [Member] | August 2019 Warrant [Member]
Issuance of common stock, shares	5,444,444
2018 Brio Warrant Amendment [Member] | Maximum [Member] | Brio Master Fund [Member] | 2018 Brio Warrant [Member]
Warrant exercise price		$ 0.135
Warrant		466,989
2018 Brio Warrant Amendment [Member] | Minimum [Member] | Brio Master Fund [Member] | 2018 Brio Warrant [Member]
Warrant exercise price		$ 0.28
Warrant		434,783
2019 Brio Amendment [Member] | Maximum [Member] | Brio Master Fund [Member] | Brio 2019 Warrant [Member]
Warrant exercise price		$ 0.28
Deemed warrant exercise price		$ 0.23
Warrant to purchase of common stock		1,183,575
2019 Brio Amendment [Member] | Minimum [Member] | Brio Master Fund [Member] | Brio 2019 Warrant [Member]
Warrant exercise price		$ 0.23
Deemed warrant exercise price		$ 0.135
Third Investor [Member] | Stock Purchase Agreement [Member]
Issuance of common stock, shares					4,000,000
Cash consideration					$ 640,000
Third-Party Investors [Member] | Stock Purchase Agreement [Member]
Issuance of common stock, shares							1,250,000
Share issue price per share							$ 0.16
Cash consideration							$ 200,000
Alpha and Brio [Member]
Issuance of common stock, shares										739,291
Cashless exercise of warrants, shares										1,836,155
Company Chief Executive Officer [Member] | Purchase Agreement [Member]
Issuance of common stock, shares				5,000,000
Share issue price per share				$ 0.18
Cash consideration				$ 900,000
Purchased remaining interest percentage				21.80%
Ownership percentage				100.00%
Accumulated deficit				$ 412,377
Chief Technology Officer [Member] | Purchase Agreement [Member]
Issuance of common stock, shares				5,000,000
Cash consideration				$ 900,000
Mr.Sean Fitzpatrick [Member] | Services Agreement [Member] | Service-Based Stock Options [Member]
Stock based compensation description			In connection with Mr. Fitzpatrick's transition, the Company agreed to amend that certain services agreement entered into on July 23, 2018, by and between the Company and Mr. Fitzpatrick, to (i) decrease the number of options to purchase the Company's common stock previously granted to Mr. Fitzpatrick from 5,000,000 options to 2,500,000 options, 650,000 of which are fully vested as of the effective date and (ii) amend the vesting schedule for the remaining 1,850,000 performance options to include four performance metrics that, if met, each trigger the vesting of 462,500 options.
Options to purchase shares of common stock			5,000,000
Options granted fully vested			650,000
Remaining performance options			1,850,000
Trigger the vesting of options			462,500
Number of shares cancelled during period			1,850,000
Purchase of common stock exercise price			$ 0.30
Mr.Sean Fitzpatrick [Member] | Services Agreement [Member] | Service-Based Stock Options [Member] | Maximum [Member]
Options to purchase shares of common stock			2,500,000
Mr.Sean Fitzpatrick [Member] | Services Agreement [Member] | Performance-Based Stock Options [Member]
Stock based compensation description			In connection with Mr. Fitzpatrick's transition, the Company agreed to amend that certain services agreement entered into on July 23, 2018, by and between the Company and Mr. Fitzpatrick, to (i) decrease the number of options to purchase the Company's common stock previously granted to Mr. Fitzpatrick from 5,000,000 options to 2,500,000 options, 650,000 of which are fully vested as of the effective date and (ii) amend the vesting schedule for the remaining 1,850,000 performance options to include four performance metrics that, if met, each trigger the vesting of 462,500 options.
Options to purchase shares of common stock			5,000,000
Options granted fully vested			650,000
Remaining performance options			1,850,000
Trigger the vesting of options			462,500
Number of shares cancelled during period			1,850,000
Purchase of common stock exercise price			$ 0.30
Mr.Sean Fitzpatrick [Member] | Services Agreement [Member] | Performance-Based Stock Options [Member] | Maximum [Member]
Options to purchase shares of common stock			2,500,000
Three Employees, Two Advisory Board Members and One Vendor [Member]
Stock based compensation description										These stock options have a contractual term of 10 years and vest in 1/3 increments over a two to three year period.
Stock options issued						2,400,000				2,400,000
Contractual term										10 years

XML

Stockholders' Equity - Schedule of Option Activity (Details)	6 Months Ended
	Jun. 30, 2020 $ / shares shares
Service-Based Stock Options [Member]
Number of Options, Beginning Balance | shares	15,045,000
Number of Shares, Granted | shares	2,400,000
Number of Shares, Cancelled | shares	(1,875,000)
Number of Shares, Expired | shares
Number of Options, Ending balance | shares	16,070,000
Number of Options, Exercisable, Beginning | shares	11,805,416
Number of Options, Exercisable, Ending | shares	14,430,416
Exercise Price per Share, Cancelled	$ 0.30
Exercise Price per Share, Expired
Weighted Average Remaining Contractual Life, Beginning	4 years 9 months 11 days
Weighted Average Remaining Contractual Life, Granted	7 years 3 months 15 days
Weighted Average Remaining Contractual Life, Cancelled	7 years 6 months
Weighted Average Remaining Contractual Life, Expired	0 years
Weighted Average Remaining Contractual Life, Ending	4 years 6 months 21 days
Weighted Average Remaining Contractual Life, Exercisable, Beginning	3 years 9 months 3 days
Weighted Average Remaining Contractual Life, Exercisable, ending	4 years 4 months 17 days
Weighted Average Exercise Price per Share, Beginning balance	$ 0.30
Weighted Average Exercise Price per Share, Granted	0.57
Weighted Average Exercise Price per Share, Cancelled	0.30
Weighted Average Exercise Price per Share, Expired
Weighted Average Exercise Price per Share, Ending balance	0.34
Weighted Average Exercise Price per Share, Exercisable, Beginning	0.25
Weighted Average Exercise Price per Share, Exercisable, Ending	0.26
Service-Based Stock Options [Member] | Minimum [Member]
Exercise Price per Share, Beginning balance	0.20
Exercise Price per Share, Granted	0.23
Exercise Price per Share, Ending balance	0.16
Exercise Price per Share, Exercisable, Beginning	0.20
Exercise Price per Share, Exercisable, Ending	0.20
Service-Based Stock Options [Member] | Maximum [Member]
Exercise Price per Share, Beginning balance	0.40
Exercise Price per Share, Granted	1.50
Exercise Price per Share, Ending balance	1.50
Exercise Price per Share, Exercisable, Beginning	0.40
Exercise Price per Share, Exercisable, Ending	$ 0.40
Performance-Based Stock Options [Member]
Number of Options, Beginning Balance | shares	6,825,000
Number of Options, Ending balance | shares	6,275,000
Number of Options, Exercisable, Beginning | shares	3,175,000
Number of Options, Exercisable, Ending | shares	3,175,000
Weighted Average Exercise Price per Share, Beginning balance	$ 0.34
Weighted Average Exercise Price per Share, Ending balance	0.36
Weighted Average Exercise Price per Share, Exercisable, Beginning	0.40
Weighted Average Exercise Price per Share, Exercisable, Ending	0.40
Performance-Based Stock Options [Member] | Maximum [Member]
Exercise Price per Share, Beginning balance	0.40
Exercise Price per Share, Cancelled	0.30
Exercise Price per Share, Ending balance	1.50
Exercise Price per Share, Exercisable, Beginning	0.40
Exercise Price per Share, Exercisable, Ending	$ 0.40

XML

Stockholders' Equity - Schedule of Warrant Outstanding and Exercisable (Details) - Warrant [Member]	6 Months Ended
	Jun. 30, 2020 $ / shares shares
Number of Warrants, Beginning balance | shares	11,326,621
Number of Warrants, Granted | shares	5,642,715
Number of Warrants, Exercised | shares	(9,930,759)
Number of Warrants, Expired | shares
Number of Warrants, Ending balance | shares	7,038,181
Number of Warrants, Exercisable, Beginning | shares	10,330,244
Number of Warrants, Exercisable, Ending | shares	5,745,608
Exercise Price per Share, Expired
Weighted Average Remaining Contractual Life, Beginning	6 years 7 days
Weighted Average Remaining Contractual Life, Granted	5 years 5 months 27 days
Weighted Average Remaining Contractual Life, Exercised	1 year 5 months 12 days
Weighted Average Remaining Contractual Life, Expired	0 years
Weighted Average Remaining Contractual Life, Ending	5 years 7 months 2 days
Weighted Average Remaining Contractual Life, Exercisable, Beginning	6 years 2 months 27 days
Weighted Average Remaining Contractual Life, Exercisable, Ending	5 years 7 months 13 days
Weighted Average Exercise Price per Share, Beginning balance	$ 0.25
Weighted Average Exercise Price per Share, Granted	0.12
Weighted Average Exercise Price per Share, Exercised	0.14
Weighted Average Exercise Price per Share, Expired
Weighted Average Exercise Price per Share, Ending balance	0.31
Weighted Average Exercise Price per Share, Exercisable, Beginning	0.31
Weighted Average Exercise Price per Share, Exercisable, Ending	0.34
Minimum [Member]
Exercise Price per Share, Beginning balance	0.20
Exercise Price per Share, Granted	0.13
Exercise Price per Share, Exercised	0.13
Exercise Price per Share, Ending balance	0.13
Exercise Price per Share, Exercisable, Beginning	0.20
Exercise Price per Share, Exercisable, Ending	0.13
Maximum [Member]
Exercise Price per Share, Beginning balance	0.50
Exercise Price per Share, Granted	0.14
Exercise Price per Share, Exercised	0.14
Exercise Price per Share, Ending balance	0.50
Exercise Price per Share, Exercisable, Beginning	0.50
Exercise Price per Share, Exercisable, Ending	$ 0.50

XML

Leases (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2020	Feb. 28, 2018
Monthly payment for first twelve months	$ 2,106
Monthly payment for second twelve months	2,149
Monthly payment for third twelve months	2,235
Security deposit for lease	2,235
Lease Agreement [Member]
Lease term		3 years
Justin Schreiber [Member]
Rent expenses	$ 4,000

XML

Leases - Schedule of Leases (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Right of Use Asset	$ 19,990	$ 23,625
Lease liability	$ 28,917	$ 29,978

XML

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended		12 Months Ended
	Apr. 30, 2017	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2016	Dec. 31, 2019
Proceeds from common stock		$ 250,000
Subscription Agreement [Member]
Number of share issued for common stock	217,390
Warrants issued for common stock	108,696
Accounts payable and accrued expenses			$ 0			$ 0
Employment and Consulting Agreement [Member]
Expiring agreement description				The Company has entered into various agreements with officers, directors, employees and consultants that expire in one to five years.
180 Day Anniversary Agreement [Member] | Subscription Agreement [Member]
Performance fee	$ 50,000
Pilaris Laboratories, LLC [Member]
Percentage of net income					10.00%
Pilaris Laboratories, LLC [Member] | CVLB PR [Member]
Agreements of performance fees, description					As consideration for granting Conversion Labs PR this license, Pilaris will receive on quarterly basis, 10% of the net income collected by the licensed products based on the following formula: Net Income = total income - cost of goods sold - advertising and operating expenses directly related to the marketing of the licensed products. In addition, Conversion Labs PR shall pay Pilaris a performance fee of $50,000 on the 180-day anniversary of the agreement and an additional $50,000 performance fee on the 365-day anniversary of the agreement.
Pilaris Laboratories, LLC [Member] | CVLB PR [Member] | 180 Day Anniversary Agreement [Member]
Performance fee					$ 50,000
Pilaris Laboratories, LLC [Member] | CVLB PR [Member] | 365 Day Anniversary Agreement [Member]
Performance fee					$ 50,000
License fee				$ 100,000
M.Alphabet, LLC [Member]
Agreements of performance fees, description				The Company shall pay Alphabet a royalty equal to 13% of Gross Receipts (as defined in the Agreement) realized from the sales of Licensed Products. Further, so long as the Agreement is not previously terminated, the Company, also agreed to pay Alphabet $50,000 on the 120-day anniversary of the Agreement and an additional $50,000 on the 360-day anniversary of the Agreement.
Percentage for royalty				13.00%
Option term				10 years
Number of stock options issued				100,000
Option to purchase common stock exercise price				$ 0.50
M.Alphabet, LLC [Member] | Common Stock One [Member]
Number of stock options issued				100,000
Option to purchase common stock exercise price				$ 0.50
Proceeds from common stock				$ 7,500,000
M.Alphabet, LLC [Member] | Common Stock Two [Member]
Number of stock options issued				100,000
Option to purchase common stock exercise price				$ 0.50
Proceeds from common stock				$ 10,000,000
M.Alphabet, LLC [Member] | Common Stock Three [Member]
Number of stock options issued				200,000
Option to purchase common stock exercise price				$ 0.75
Proceeds from common stock				$ 20,000,000
M.Alphabet, LLC [Member] | 120 Day Anniversary Agreement [Member]
Performance fee				50,000
M.Alphabet, LLC [Member] | 360 Day Anniversary Agreement [Member]
Performance fee				$ 50,000

XML

Related Party Transactions (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Mr. Schreiber [Member] | Minimum [Member] | Office Space [Member]
Payment for rent	$ 4,000
Mr. Schreiber [Member] | Maximum [Member] | Office Space [Member]
Payment for rent	5,000
JLS Ventures, LLC [Member] | Puerto Rico Office Space [Member]
Payment for rent	15,000	$ 12,000
BV Global Fulfillment [Member] | Current Chief Executive Officer [Member] | Accounts Payable and Accrued Liabilities [Member]
Due to related party	161,823		$ 53,026
BV Global Fulfillment [Member] | Current Chief Executive Officer [Member] | Minimum [Member]
Payment of related party	13,000
BV Global Fulfillment [Member] | Current Chief Executive Officer [Member] | Maximum [Member]
Payment of related party	$ 16,000

XML

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)		1 Months Ended
	Jul. 27, 2020	Aug. 31, 2020
Convertible promissory note	$ 1,500,000
Interest rate percentage	1.25%
Debt instrument maturity date	Jan. 24, 2021
Preferred stock, par value	$ 0.001
Preferred stock value	$ 2,500,000
Adjusted exercise price		$ 0.35
Warrants to purchase common stock		2,634,228
Offering discount price		$ 0.05
Warrant Holders [Member]
Adjusted exercise price		$ 0.40